Skip to main content
Cureus logoLink to Cureus
. 2024 May 27;16(5):e61165. doi: 10.7759/cureus.61165

Mutations in the TP53, VEGFA, and CTH Genes as Key Molecular Markers for the Diagnosis of Glioblastoma

Sardar S Khalil 1, Abbas Salihi 2,
Editors: Alexander Muacevic, John R Adler
PMCID: PMC11202102  PMID: 38933650

Abstract

Background

Brain cancer, particularly glioblastoma (GBM), is a global health problem. Despite therapy advances, GBM patients have a poor prognosis. The progression and etiology of GBM may be linked to gene polymorphisms in the VEGFA, TP53, and CTH genes, among others. However, the genetic variations and their interaction in GBM are not fully understood. This study examines the effects of mutations in the VEGFA, TP53, and CTH genes on GBM.

Methodology

Tissue and blood samples were obtained for hematological, biochemical, and genetic analysis from 18 patients diagnosed with GBM as well as 28 healthy individuals. Standard methods were adopted to perform hematological and biochemical analyses, whereas mutational landscape and expression profiles were obtained from publicly accessible databases. Tissue samples were processed for genomic DNA extraction, and genotype determination was carried out through conventional polymerase chain reaction (PCR) and Sanger sequencing.

Results

The study involved 18 patients with grade IV GBM before treatment and 28 healthy individuals. The patients consisted of 11 men (61%) and seven females (39%), while healthy individuals included 14 (50%) males and 14 (50%) females. Sixty-seven percent of patients were under 50, 17% between 51 and 60, and 17% over 61, compared to healthy individuals who were 61% under 50, 7% between 51 and 60, and 32% over 60. GBM patients showed higher neutrophil and monocyte counts (median 81% (63.9, 83.5) and 4.2% (3.8-7.3)), respectively, and lower lymphocyte counts (median 13.4% (8.8, 28.40)) compared to controls. The median values of aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) showed no significant differences between the control and GBM groups. GBM patients had significantly higher median CRP levels of 2.55 (1.6, 98) than controls. Analysis of databases revealed a high prevalence of mutations in TP53, with splice region variants, missense variants, and intron variants being the most common. VEGFA and CTH also displayed mutations, primarily missense and intron variants. Gene expression analysis showed significantly higher levels of TP53 and VEGFA in GBM patients compared to controls. CTH expression also exhibited a slight increase in GBM patients. Sanger sequencing identified three mutations in the TP53 gene, including a novel mutation (11915C>A) not previously reported in external databases. Additionally, novel mutations were found in the VEGFA (841G>GA, 919T>TG) and CTH (28398A>AC, 28399A>AT) genes.

Conclusions

This study highlights the immune dysregulation, inflammation, and genetic variations in GBM. The findings emphasize the potential importance of the TP53, VEGFA, and CTH genes as targets for therapies and diagnostic biomarkers of GBM. Further study is necessary to comprehend these genetic variations' functional implications and their use in personalized GBM treatment.

Keywords: gene mutation, cth, vegfa, tp53, glioblastoma

Introduction

Glioblastoma (GBM) is the most common and deadly primary CNS malignancy. Brain tumors and nervous system malignancies will account for 300,000 new cases and 250,000 deaths a year, 48% of CNS tumors are GBM [1]. In 2021, the WHO classified brain tumors according to genetic changes and histologic characteristics. The four types of GBM are adult-type diffuse gliomas, pediatric-type diffuse low-grade gliomas, pediatric-type diffuse high-grade gliomas, and confined astrocytic gliomas [2].

Overexpression of vascular endothelial growth factor (VEGF) is a feature of GBM. VEGF stimulates extensive angiogenesis and has a direct correlation with the malignancy and prognosis of GBM [3]. Accordingly, single nucleotide polymorphisms of this gene could play an important role in structural and functional alterations, leading to overexpression of this gene in GBM [4]. The mutant variant of TP53 promotes tumor cell proliferation and accelerates the malignant transformation of astrocytic tumors [5]. This variation is often connected with the IDH-1 mutation (65%-90% of cases), but the TP53 gene mutation occurs in only 30% of IDH wild-type GBM [6].

Hydrogen sulfide (H2S) is widely recognized as a carcinogenic gas and has the potential to be a target for cancer therapy and detection due to its role in cancer progression. Some enzymes, like cystathionine β-synthase (CBS) and CTH, need pyridoxal 5' phosphate to do their job. These enzymes are responsible for the conversion of L-cysteine into endogenous H2S inside human tissues. The liver, kidney, and brain contain abundant amounts of CTH [7]. Different types of cancer, including prostate cancer, gastric cancer, and melanoma cells, exhibit an increase in CTH [8]. Our research group has found a number of clinically important mutations in colorectal cancer [9] and lung adenocarcinoma [10]. However, little research currently investigates a putative relationship between GBM-causing genes and H2S-producing genes. This study examines the roles and implications of numerous mutations in the TP53, VEGFA, and CTH genes and their relationship to GBM.

Materials and methods

Tissue and blood collection

Blood and formalin-fixed paraffin-embedded (FFPE) tissue blocks of 18 GBM patients were collected from the Central Public Health Laboratory and Private Laboratories in Duhok and Erbil governorates, respectively. FFPE tissue samples were obtained and kept at room temperature (20-22°C) before DNA extraction and genotyping. The tumor samples from the paraffin blocks were macro-dissected. All specimens were placed in Eppendorf containers to avoid tissue cross-contamination. Also, blood samples were collected from GBM and healthy individuals for hematological and biochemical analysis.

Hematological and biochemical measurements

The total white blood cell counts and differential leukocyte counts were measured using a CBC Coulter Counter Convergys X3 (Convergent Technologies GmbH & Co. KG, Germany) as per the manufacturer's instructions. To check the levels of aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), and C-reactive protein (CRP) in the blood, we used a Cobas Integra 400 Plus analyzer and an Elecsys CEA ready-to-use reagent kit from Roche Diagnostics, Basel, Switzerland. This detection technique utilizes electrochemiluminescence to quantify the immunoreactivity.

Mutational landscape and expression profiles data retrieval

The present study examined the significance of mutations occurring in the TP53, VEGFA, and CTH genes as potential molecular markers in GBM. We retrieved data on mutations from the International Cancer Genome Consortium (ICGC) Data Portal (https://dcc.icgc.org/) and the COSMIC Mutational Signatures (https://www.sanger.ac.uk/tool/cosmic/) to achieve this objective. The COSMIC Mutational Signatures database provided an extensive collection of somatic mutation data encompassing a variety of cancer types, including GBM. This facilitated our analysis by giving us access to a wide variety of mutation profiles. The ICGC data portal provided supplementary, curated mutation data that was specific to GBM cases, thereby boosting the comprehensiveness and precision of our mutational analysis.

Subsequently, expression data was retrieved from the Gene Expression Database of Normal and Tumour Tissues (GENT2) (http://gent2.appex.kr/gent2/). This resource was used to investigate gene expression patterns in GBM samples that were associated with TP53, VEGFA, and CTH genes. Using GENT2, we successfully analyzed the transcriptional activity of these genes in a wide variety of GBM specimens, generating important information regarding their possible involvement in the progression and pathogenesis of GBM.

DNA extraction and quantification

Genomic DNA was extracted from FFPE tissues of GBM using a commercially available kit, the FavorPrepTM Tissue Genomic DNA Extraction Kit (Favorgen, Taiwan), following the manufacturer’s protocols. DNA was extracted and purified from 18 specimens (FFPE of GBM tissue samples). Each sample block, 10 µm in diameter, was cut and divided into ten equal sections using a semi-automated microtome (HM 340E; Thermo Fisher Scientific, Waltham, USA). Agarose gel electrophoresis and Red-Safe staining were employed to examine the quality of the extracted DNA. The DNA content was then measured using a Thermo Scientific Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, USA), and the purity of the DNA was determined using an optimal A260/A280 absorbance ratio of 1.8.

Genotype determination

In this study, we selected three commonly studied variations in the TP53, VEGFA, and CTH genes. The purified DNA was amplified individually for each genetic variant using conventional PCR on a Veriti 96-thermal cycler (Thermo Fisher Scientific, Waltham, USA) using the following primers: TP53 forward, 5′-TCCCCCTTGCCGTCCCA-3′ and reverse, 5′-CTGGTGCAGGGGCCACGC-3′; VEGFA forward, 5′-CTCGGTGCTGGAATT TGATATTC-3′ and reverse, 5′-CAAAAGCAGGTCACTCACTTTGC-3′; CTH forward, 5′-GGACTTCTTGAGGAGTTGAAGC-3′ and reverse, 5′-ATTCTCACCTCCTTCAGAGGC-3′.

Initially, a ready-to-use master mix (ADDBIO INC., Daejeon, Korea) was used, containing Taq DNA polymerase, dNTPs, KCl, and reaction buffer. The following thermocycling conditions have been used for PCR: initial denaturation at 95°C for 5 min, followed by 35 cycles of 95°C for 30 sec; different annealing temperatures were used for each polymorphism (TP53 at 60°C, VEGFA at 55°C, CTH at 54°C) for 30 sec; and elongation at 72°C for 1 min, followed by a final extension step at 72°C for 5 min. The PCR products for TP53 and CTH were separated by 2% agarose gel electrophoresis. VEGFA was separated on 3% agarose gel electrophoresis, compared with the 100-bp DNA marker (GDSBio, China), and stained with a safe dye (DSView Nucleic Acid Stain, GDSBio) before being cast into the tray and visualized using a gel documentation system (UV transilluminator UVP, UK). Following the PCR procedure, the products were sent for sequencing using the same forward primers for each particular polymorphism using an automatic ABI PRISM 3130 DNA sequencer (Applied Biosystems, USA). Analysis of Sanger sequencing data was achieved using the Mutation Surveyor software (Soft Genetics, State College, USA), and the mutation result was compared with public databases, including gnomAD, dbSNP, ClinVar, and COSMIC.

Statistical analysis

For biochemical and hematological analysis, comparisons between patients with GBM and healthy individuals were performed using a Mann-Whitney test, and values were presented as medians and 25% and 75% quartiles. Whereas for gene expression retrieved from the GENT2 database, comparisons between patients with GBM and healthy individuals were performed using an unpaired t-test, and values were presented as mean±SEM. All data were subjected to normality testing, including the D'Agostino and Pearson omnibus, Shapiro-Wilk, and KS tests. The graphics, computations, and statistical analyses were generated using GraphPad Prism software (version 10; GraphPad Software, Inc.). A p-value of <0.05 was considered statistically significant.

Ethical considerations

The Scientific Research Division's Research Ethics Committee of the University of Duhok approved the study protocol under approval number (15092021-9-13), and all procedures contributing to this work met national and institutional human experimentation committees' ethical standards and the Declaration of Helsinki.

Results

Patient characteristics

This study includes a cohort of 18 GBM patients and 28 healthy individuals. Among these patients, 11 (61.11%) were men and seven (38.88%) were women. Individuals who participated were categorized based on their age, with 12 (66.66%) being under the age of 50, three (16.66%) being between the ages of 51 and 60, and three (16.66%) being older than 61, while healthy individuals were 14 (50%) male and 14 (50%) female, with 17 (60.71) being under the age of 50, two (7.14%) being between the ages of 51 and 60, and nine (32.14%) being older than 61. All patients included in this study were diagnosed with GBM tumors, specifically grade IV.

Hematological and biochemical analysis

In the control group, the median WBC count was 6.46 (5.57, 9.13) (106/µL), but in GBM patients, it was 9.1 (5.8, 14.5) (106/µL). However, this difference was not statistically significant. However, WBC subgroups differed significantly. Neutrophil counts were significantly higher (p≤0.05) in GBM patients than in controls, with a median of 81% (63.9, 83.5) in GBM vs. 62.3% (57.2, 70) in controls. In GBM patients, lymphocyte counts were significantly lower (p≤0.01) than in controls, with a median of 13.4% (8.8, 28.40) in GBM vs. 34.01% (28.2, 37.8) in controls. Monocyte counts were considerably greater (p≤0.05) in GBM patients compared to the control median: 4.2% (3.8-7.3) in GBM vs. 3.2% (1.8-4.1) in controls (Figure 1).

Figure 1. Comparison between the total number of WBCs, neutrophils, lymphocytes, and monocytes in healthy individuals and patients with GBM.

Figure 1

(A) No significant changes were observed in the total number of WBCs. (B) The percentage of neutrophils was significantly increased in patients with GBM compared to healthy individuals. (C) The percentage of lymphocytes was significantly decreased in patients with GBM compared to healthy individuals. (D) The percentage of monocytes was significantly increased in patients with GBM compared to healthy individuals. The comparison was performed using an unpaired t-test.

*p<0.05; **p<0.01 vs. healthy individuals; GBM: glioblastoma; WBC: white blood cell

The median values of AST 18 (15.75, 21) in control vs. 16 (2.55, 27.5) in GBM, ALT 14 (11, 20) in control vs. 11.6 (2.55, 26) in GBM, and ALP (61.2 (54.38, 73.03) in control vs. 68 (2.43, 138.3) in GBM) showed no statistically significant differences. GBM patients had significantly higher (P≤0.01) median CRP levels of 2.55 (1.6, 98) in GBM vs. 0.15 (0.1, 0.2) in control (Figure 2).

Figure 2. Liver function markers and CRP levels in healthy individuals and GBM patients.

Figure 2

No significant changes were observed in the AST (IU/L) (A), ALT (IU/L) (B), and ALP (IU/L) (C) in patients with GBM compared to healthy individuals. (D) The level of CRP (mg/L) was significantly increased in patients with GBM compared to healthy individuals. The comparison was performed using the Mann-Whitney test.

**p<0.01 vs. healthy individuals; GBM: glioblastoma; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphatase; CRP: C-reactive protein

Mutation and expression retrieval from databases

The distribution of mutations within these genes retrieved from the gnomAD database, including various classes of mutations, is briefly presented in Table 1. A total of 2041 mutations were identified in the TP53 gene, comprising significant mutations in the splice region variant (70), missense variant (564), and intron variant (902). VEGFA showed a total of 1862 mutations, with missense variant (593), intron variant (772), and synonymous variant (246) being the most prevalent. A considerable percentage of the 1839 mutations identified in CTH were intron variant (920), missense variant (509), and splice region variant (52).

Table 1. Summary of mutations in the TP53, VEGFA, and CTH genes in all types of cancer retrieved from the gnomAD database.

Genes Total 3prime UTR variant 5prime UTR variant Frameshift variant Inframe deletion Inframe insertion Intron variant Missense variant Splice acceptor variant Splice donor variant Splice region variant Start lost Stop gained Stop lost Stop retained variant Synonymous variant
TP53 2041 109 124 6 19 1 902 564 13 6 70 5 15 1 2 204
VEGFA 1862 64 67 39 4 2 772 593 5 8 36 3 19 3 1 246
CTH 1839 40 64 40 2 - 920 509 15 13 52 2 16 1 - 165

A summary of the mutations retrieved from the ICGC database is presented in Table 2 and Table 5 in Appendices, which classify them according to their clinical significance and impact. A total of 1079 high-impact mutations were identified in TP53, with 136 of them being classified as clinically significant. The majority of these mutations were composed of single-base substitutions. Among them were 25 missense mutations, one stop gained mutation, and nine likely pathogenic mutations, in addition to various pathogenic classifications: nine pathogenic, eight pathogenic/likely pathogenic, and nine likely pathogenic. Twenty-two high-impact mutations were observed in VEGFA, two of which were stop-gain mutations. Three of the 84 high-impact mutations identified in CTH were missense mutations. Notably, in this dataset, no clinically significant mutations were identified for VEGFA and CTH genes.

Table 2. Summary of mutations in the TP53, VEGFA, and CTH genes in GBM retrieved from the ICGC database.

GBM: glioblastoma; ICGC: International Cancer Genome Consortium

Genes High impact mutations Clinically significant mutations Glioblastoma Type of mutations Consequences Clinical significance
TP53 1079 136 26 Single base substitution 25 Missenses, 1 Stop Gained 9 Pathogenic, 8 Pathogenic/Likely pathogenic, 9 Likely pathogenic
VEGFA 22 0 2 Single base substitution 2 Stop Gained Non-pathogenic
CTH 84 0 3 Single base substitution 3 Missense Non-pathogenic

The types and frequencies of COSMIC database mutations are summarized in Table 3 and Table 6 in Appendices. TP53 had a total of 773 mutations, with the majority being substitution missense mutations (515), deletion frameshift mutations (67), and substitution nonsense mutations (46). VEGFA showed a lower number of mutations, including 12 mutations, consisting of five substitution missense mutations and three substitution silent mutations. CTH had the lowest mutation number with a total of four mutations, mostly comprising two substitution missense mutations and two unknown mutations. Notably, the data we collected did not contain complex frameshift or whole gene deletion mutations in VEGFA or CTH.

Table 3. Summary of the mutations in the TP53, VEGFA, and CTH genes in GBM retrieved from the COSMIC database.

GBM: glioblastoma

Genes Total Complex frameshift Deletion frameshift Deletion In frame Frameshift Insertion frameshift Insertion in frame Substitution coding silent Substitution missense Substitution nonsense Unknown Whole gene deletion
TP53 773 2 67 25 21 21 6 20 515 46 49 1
VEGFA 12 - - - - - - 2 3 2 5 -
CTH 4 - - - - - - - 2 - 2 -

The analysis of gene expression in the GENT2 database showed considerable differences between the control group and patients diagnosed with GBM (Figure 3). TP53 expression was significantly higher (p≤0.001) in GBM patients (7.837±0.022) than in controls (6.549±0.033). Similarly, VEGFA expression was significantly greater (p≤0.001) in GBM (9.698±0.023) than in controls (8.655±0.031). Additionally, there was a modest elevation (p≤0.01) in CTH expression in GBM patients (7.376±0.017) in comparison to the control group (7.279±0.024).

Figure 3. TP53, VEGFA, and CTH gene expression in healthy individuals and patients with GBM retrieved from the GENT2 database.

Figure 3

The log2 expression values of TP53 (A), VEGFA (B), and CTH (C) genes were significantly increased in patients with GBM compared to healthy individuals. The comparison was performed using an unpaired t-test.

**p<0.01; ****p<0.001 vs. healthy individuals; GBM: glioblastoma

Mutation analysis

In the present study, we elected to genotype three different single nucleotide polymorphisms in the TP53, VEGFA, and CTH genes. Following DNA sequencing, we used a Mutation Surveyor to identify mutations in the TP53, VEGFA, and CTH genes (Table 4). The most nucleotide substitution that occurred in the TP53 gene was nine times C→G. The variant mutation (11897C>G) on chromosome position (17:7579472) has been previously described in external public databases, and its variant percentage in the present study was 100%. However, the C→A substitution in the mutation variants (11915C>A) on chromosome position (17:7579454) has not been previously described in the external databases, also its variant percentage was 100%. While, the C→CT substitution in the mutation variants (11846C>CT) also occurred on chromosome position (17:7579548), causing a change in amino acid Serine to Isoleucine, in which this mutation was not found in the external databases, and its variant percentage was 12.5%.

Table 4. Variants identified in TP53, CTH, and VEGFA genes GBM patients analyzed with mutation DNA variant analysis.

GBM: glioblastoma

Genes Chromosome position Exon Mutation genotype Mutation Heterozygous/homozygous Variants Variant percentage Amino acid change External database
VEGF 6:43738350 1 C>CG substitution Heterozygous 905C>CG 37.5% None dbSNP:2010963
  6:43738350 1 C>G substitution Homozygous 905C>G 50% None dbSNP:2010963
  6:43738364 1 T>TG substitution Heterozygous 919T>TG 12.5% None Not found
  6:43738173 1 G>GA substitution Heterozygous 841G>GA 12.5% None Not found
TP53 17:7579472 4 C>G substitution Homozygous 11897C>G 100% None dbSNP:1042522
  17:7579454 4 C>A substitution Homozygous 11915C>A 100% None Not found
  17:7579548 4 C>CT substitution Heterozygous 11846C>CT 12.5% Serine/Isoleucine Not found
CTH 1:70904800 12 G>GT substitution Heterozygous 28400G>GT 25% Serine/Isoleucine dbSNP:1021737
  1:70904895 12 A>AG substitution Heterozygous 28495A>AG 25% None Not found
  1:70904977 12 T>TA substitution Heterozygous 28577T>TA 25% None Not found
  1:70905011 12 C>CA substitution Heterozygous 28611C>CA 25% None Not found
  1:70904798 12 A>AC substitution Heterozygous 28398A>AC 25% None Not found
  1:70904799 12 A>AT substitution Heterozygous 28399A>AT 25% Serine/Cysteine Not found
  1:70904776 12 T>TC substitution Heterozygous 28376T>TC 33.3% None Not found

In the VEGFA gene, heterozygous substitution and one homozygous substitution in the mutation variants (905C>CG and 905C>G) on chromosome position (6:43738350) has occurred in GBM patients, and this mutation has been previously described; its variant percentage was 37.5%; while, the G→GA substitution with mutation variant (841G>GA) that occurred on chromosome position (6:43738173), in which this mutation was not found previously in the databases, and its variant percentage was 12.5%. However, the T→TG substitution in the mutation variants (919T>TG) on chromosome position (6:43738364), in which this mutation was not found previously in the databases, and its variant percentage was 12.5%.

A total of seven mutations were identified on chromosome 1 at various positions of the CTH gene. Three of the newly found mutant variants in the CTH gene are associated with a change in amino acid level. The T→TC heterozygous substitution with mutation variant (28376T>TC) on chromosome position (1:70904776). However, four mutation variants (28400G>GT, 28495A>A, 28577T>T, and 28611C>C) on chromosome position (1:70904800, 1:70904895, 1:70904977 and 1:70905011) no amino acid changes were detected in any of them except the variants (28400G>GT,403S>S). Two mutation variants (28398A>AC and 28399A>AT) on chromosome position (1:70904798 and 1:70904799) caused a change in amino acid, nor were any of them reported in external databases, and its variant percentage for all mutations was 25%.

Discussion

This study examined a group of 18 patients diagnosed with GBM, an extremely severe form of brain cancer. The patient group included more men than women, which is consistent with the reported higher incidence of GBM in men [11]. The majority of individuals in both the patient (66.66%) and control (60.71%) groups were under 50 years old, with fewer falling into the 51-60 and above 61 age categories. This might be attributed to the rarity of GBM in younger individuals, along with the increased death rate related to the disease in elderly people [12].

Comparing the blood parameters of GBM patients to those of a control group shows that the development of GBM is linked to significant changes in immune cell profiles and signs of inflammation. GBM patients significantly increased their neutrophil levels, indicating the presence of a pro-inflammatory condition in the tumor microenvironment [13]. In contrast, GBM patients had substantially lower lymphocyte numbers, indicating the presence of immune suppression or evasion mechanisms used by the tumor [14]. Furthermore, the number of monocytes was considerably greater in individuals with GBM, which may indicate the presence of tumor-associated macrophages infiltrating the tumor [15]. In addition, the GBM immunological microenvironment is inhabited by myeloid cells, including tumor-associated macrophages, myeloid-derived suppressor cells, neutrophils, and dendritic cells, indicating an increase in myeloid progenitors in GBM [16]. Moreover, the markedly elevated levels of CRP in individuals with GBM indicate the presence of systemic inflammation associated with the tumor [17]. Although there were changes in the immune system, the liver function markers AST, ALT, and ALP did not show any statistically significant changes between GBM patients and controls. Sarganas et al. [18] showed a substantial increase in liver function markers after temozolomide therapy. These results emphasize the complicated connection between immune dysregulation and inflammatory processes in GBM and highlight the potential diagnostic and therapeutic significance of monitoring immunological and inflammatory markers in GBM patients.

An in-depth examination of mutations retrieved from multiple databases provides essential information on the molecular basis of cancer, with a specific emphasis on essential genes, including TP53, VEGFA, and CTH genes. The gnomAD database revealed significant variations in the distribution of mutations across these genes, emphasizing the broad spectrum of mutation types and their incidences. An extensive number of mutations, such as splice region variants, missense variants, and intron variants, were found in the TP53 gene, indicating the complicated sequence of changes in this gene responsible for suppressing tumor growth. Variations in missense and intron mutations were frequently observed in the VEGFA and CTH genes, showcasing a diverse array of mutation patterns. The ICGC database uncovered several significant mutations in the TP53 gene, highlighting its importance in cancer development. In contrast, the VEGFA and CTH genes exhibited fewer variations, but there were noticeable differences in the kinds of mutations. Notably, there were no significant mutations found for the VEGFA and CTH genes in this dataset that had clinical significance. TP53 mutations were very widespread in the COSMIC database, exhibiting a range of mutation types such as substitution missense and deletion frameshift mutations. This indicates that the gene TP53 displays genetic heterogeneity in cancer. VEGFA and CTH genes had a lower number of alterations in comparison to TP53, primarily consisting of missense mutations. The current set of VEGFA and CTH genes did not contain any complex frameshift or whole gene deletion mutations. In general, these results provide significant knowledge about the genetic mutations in cancer-related genes and could direct future studies on targeted therapies and diagnostic approaches.

The analysis of genetic alterations from databases provided a roadmap for targeted sequencing in the second part of the study. The databases indicated the TP53 gene as a critical gene with frequent mutations, which led to further analysis in GBM patients. In these individuals, TP53 mutations, including potentially new ones, were actually found. Similarly, databases have shown possible roles for the VEGFA and CTH genes, but their changes seem to be less significant. Therefore, the current study examined the occurrence of mutations in TP53, VEGFA, and CTH, genes that are known to be associated with the development of GBM. The study identified numerous mutations in all three genes, providing valuable information on the possible genetic characteristics of GBM in the population under consideration.

The TP53 gene, which acts as a tumor suppressor, plays a crucial role in preserving the integrity of the genome and inhibiting excessive cell proliferation [19]. Several types of malignancies, including GBM, frequently exhibit TP53 mutations [20]. The investigation of the TP53 gene in GBM patients provided curious findings regarding specific mutations and their frequency. In total, three mutations in the TP53 gene of GBM patients were identified in three variants at various positions on chromosome 17. A noteworthy finding was the high frequency of C→G nucleotide substitutions in the TP53 gene, namely, the variation 11897C>G (chromosome 17:7579472), which was present in all GBM cases. This specific mutation has been recorded in external databases, confirming prior findings of its connection with the development of GBM [21]. The 11897C>G mutation in our study cohort highlights its potential importance in GBM development. In addition, we found two previously unidentified mutations in the TP53 gene: 11915C>A, which is present in 100% of cases, and 11846C>CT, which has a frequency of 12.5%. External databases have not reported the 11915C>A mutation, suggesting the possibility of discovering a new variation. Similarly, the mutation 11846C>CT, while less common, results in an alteration of the amino acid sequence from Serine to isoleucine. The functional implications of these new mutations are still unclear. More studies are needed to determine their impact on the structure and function of the p53 protein, as well as their possible role in the development of GBM.

VEGF plays a crucial role in angiogenesis, and the growth and progression of various malignancies, including GBM, are associated with elevated VEGFA expression [4]. The most frequently detected mutation was a hybrid of heterozygous and homozygous substitutions at locations 905C>CG and 905C>G on chromosome 6:43738350. We observed this mutation in colorectal cancer in our previous research but not in GMB [22]. Mutations in this specific location of the VEGFA gene have the potential to affect the signaling pathways and stimulate the growth of blood vessels in the GBM. The observed prevalence of 37.5% indicates that this mutation could have significant consequences for a significant number of GBM patients. We have also identified two new mutations in the VEGFA gene: 841G>GA (chromosome 6: 43738173) and 919T>TG (chromosome 6: 43738364). Both mutations have a prevalence rate of 12.5%. These mutations have not been previously reported in external databases. The effects of these new mutations on the structure and function of the VEGF protein are yet unclear. Therefore, these findings provide an opportunity to explore novel therapies for GBM.

The involvement of mutations in the CTH gene has been proposed in several types of cancer [9,10], but their precise contribution to the formation of GBM is still not well understood. The study of the CTH gene in GBM patients identified a combination of silent mutations and mutations that result in changes to amino acids. Amino acid substitutions occurred in three out of the seven identified mutations: 28376T>TC, 28398A>AC, and 28399A>AT. The lack of prior documentation in external databases regarding these mutations underscores the possibility of finding new variants; the functional implications of these amino acid substitutions remain unknown. The remaining four mutations (28495A>A, 284400G>GT, 28577T>T, and 28611C>C) were silent mutations. Despite their generally lower probability of significantly affecting protein function, silent mutations can still influence splicing, mRNA stability, or protein expression levels [23].

The GENT2 database's analysis of gene expression showed a clear and distinct trend in GBM patients, particularly the elevated expression of TP53 and VEGFA genes. This finding seems paradoxical for TP53, a gene that typically inhibits tumor growth and is usually suppressed in cancer [24]. However, cellular stress or DNA damage can upregulate TP53 despite the presence of inactivating mutations that render it non-functional [25,26]. To understand the role of TP53 in the current scenario, additional studies into its mutational state and how it works within GBM patients are required. However, there is widespread recognition that GBM elevates VEGFA [27]. This finding is consistent with previous investigations and emphasizes the continual importance of VEGFA signaling pathways as possible targets for treatment in GBM [28]. CTH expression in GBM showed a modest but statistically significant increase. Although the exact function of CTH in GBM is still unclear, its possible significance in cell adhesion and migration justifies additional investigation, especially in connection with GBM invasion [29]. These findings indicate an intricate interaction between variations in gene expression and the progression of GBM; therefore, further study is required to examine the practical effects of these alterations in expression and their potential as targets for medical treatment.

The study's limitations include a restricted GBM patient sample, which may limit the application of the findings to larger groups. Furthermore, the study failed to account for possible confounding factors such as comorbidities or medication usage, which might explain the observed variations in blood parameters and genetic abnormalities.

Conclusions

This study identified substantial changes in immune cell composition and inflammatory marker levels in GBM patients compared to the control group. The findings suggest a tumor microenvironment in GBM that promotes inflammation and suppresses immunological responses. Gene expression study found higher TP53 and VEGFA activity in GBM patients, possibly attributable to non-functional mutations. Further examination into the TP53 mutational status is required. The work underscores the relevance of VEGFA signaling pathways as therapeutic targets in GBM. CTH expression showed a modest increase in GBM, hinting at its potential role in GBM formation, necessitating further research. In conclusion, this study provides insight into the complex relationships between immune dysregulation, inflammation, and gene expression changes in GBM, opening the way for future strategies for therapy.

Acknowledgments

We extend our thanks to the Central Public Health Laboratory and Luay Medical Laboratory for providing formalin-fixed, paraffin-embedded (FFPE) tissue blocks. We also appreciate the patients and individuals who participated in this study.

Appendices

Table 5. Mutations in the TP53, VEGFA, and CTH genes in GBM retrieved from the ICGC database.

GBM: glioblastoma; ICGC: International Cancer Genome Consortium

TP53 Mutation ID Genomic DNA change Type Consequences
1 MU7870 chr17:g.7578406C>T single base substitution Missense: TP53 R82H, R175H, R43H|Upstream: TP53 |Exon: TP53 |Downstream: TP53
2 MU17943 chr17:g.7577539G>A single base substitution Missense: TP53 R248W, R116W, R155W|Upstream: TP53 |Exon: TP53 |Downstream: TP53
3 MU4807 chr17:g.7578190T>C single base substitution Missense: TP53 Y127C, Y88C, Y220C|Upstream: TP53 |Exon: TP53 |Downstream: TP53 |Intron: TP53
4 MU25838 chr17:g.7577548C>T single base substitution Missense: TP53 G113S, G152S, G245S|Upstream: TP53 |Exon: TP53 |Downstream: TP53
5 MU26668 chr17:g.7577568C>A single base substitution Missense: TP53 C238F, C145F, C106F|Upstream: TP53 |Exon: TP53 |Downstream: TP53
6 MU8496 chr17:g.7578265A>G single base substitution Missense: TP53 I195T, I63T, I102T|Upstream: TP53 |Exon: TP53 |Downstream: TP53 |Intron: TP53
7 MU599284 chr17:g.7578211C>T single base substitution Missense: TP53 R213Q, R81Q, R120Q|Upstream: TP53 |Exon: TP53 |Downstream: TP53 |Intron: TP53
8 MU17011 chr17:g.7577022G>A single base substitution Stop Gained: TP53 R306*, R174*|Upstream: TP53 |Exon: TP53 |Downstream: TP53 |Intron: TP53
9 MU607204 chr17:g.7577556C>T single base substitution Missense: TP53 C110Y, C242Y, C149Y|Upstream: TP53 |Exon: TP53 |Downstream: TP53
10 MU30748 chr17:g.7577538C>T single base substitution Missense: TP53 R116Q, R155Q, R248Q|Upstream: TP53 |Exon: TP53 |Downstream: TP53
11 MU24637 chr17:g.7577120C>T single base substitution Missense: TP53 R141H, R273H|Upstream: TP53 |Exon: TP53 |Downstream: TP53 |Intron: TP53
12 MU117000 chr17:g.7577114C>T single base substitution Missense: TP53 C143Y, C275Y|Upstream: TP53 |Exon: TP53 |Downstream: TP53 |Intron: TP53
13 MU11094 chr17:g.7577568C>T single base substitution Missense: TP53 C238Y, C145Y, C106Y|Upstream: TP53 |Exon: TP53 |Downstream: TP53
14 MU7717 chr17:g.7577580T>C single base substitution Missense: TP53 Y234C, Y141C, Y102C|Upstream: TP53 |Exon: TP53 |Downstream: TP53
15 MU831551 chr17:g.7577550C>T single base substitution Missense: TP53 G112D, G151D, G244D|Upstream: TP53 |Exon: TP53 |Downstream: TP53
16 MU35740 chr17:g.7578395G>A single base substitution Missense: TP53 H47Y, H179Y, H86Y|Upstream: TP53 |Exon: TP53 |Downstream: TP53
17 MU605998 chr17:g.7577551C>T single base substitution Missense: TP53 G244S, G151S, G112S|Upstream: TP53 |Exon: TP53 |Downstream: TP53
18 MU588945 chr17:g.7577096T>G single base substitution Missense: TP53 D281A, D149A|Upstream: TP53 |Exon: TP53 |Downstream: TP53 |Intron: TP53
19 MU588536 chr17:g.7577097C>G single base substitution Missense: TP53 D281H, D149H|Upstream: TP53 |Exon: TP53 |Downstream: TP53 |Intron: TP53
20 MU1664156 chr17:g.7577559G>T single base substitution Missense: TP53 S241Y, S148Y, S109Y|Upstream: TP53 |Exon: TP53 |Downstream: TP53
21 MU604332 chr17:g.7577538C>A single base substitution Missense: TP53 R248L, R116L, R155L|Upstream: TP53 |Exon: TP53 |Downstream: TP53
22 MU13250 chr17:g.7578271T>C single base substitution Missense: TP53 H193R, H61R, H100R|Upstream: TP53 |Exon: TP53 |Downstream: TP53 |Intron: TP53
23 MU1384978 chr17:g.7577560A>G single base substitution Missense: TP53 S241P, S148P, S109P|Upstream: TP53 |Exon: TP53 |Downstream: TP53
24 MU1382 chr17:g.7577517A>C single base substitution Missense: TP53 I123S, I255S|Upstream: TP53 |Exon: TP53 |Downstream: TP53
25 MU603634 chr17:g.7577535C>G single base substitution Missense: TP53 R117T, R249T|Upstream: TP53 |Synonymous: TP53 ?156|Exon: TP53 |Downstream: TP53
26 MU17274 chr17:g.7578235T>C single base substitution Missense: TP53 Y73C, Y205C, Y112C|Upstream: TP53 |Exon: TP53 |Downstream: TP53 |Intron: TP53
VEGFA Mutation ID Genomic DNA Change Type Consequences
1 MU129112547 chr6:g.43749699T>A single base substitution Stop Gained: VEGFA C143*, C341*, C184*, C364*, C115*, C347*, C161*, C167*, C323*|Exon: VEGFA |Downstream: VEGFA |Intron: VEGFA
2 MU591429 chr6:g.43748479C>T single base substitution Stop Gained: VEGFA R325*, R145*, R296*|Exon: VEGFA |Downstream: VEGFA |Intron: VEGFA
CTH Mutation ID Genomic DNA Change Type Consequences
1 MU129034369 chr1:g.70900841G>A single base substitution Missense: CTH E313K, E345K, E301K|Exon: CTH |Downstream: CTH
2 MU129069008 chr1:g.70904409G>T single base substitution Missense: CTH R332I, R320I, R364I|Exon: CTH
3 MU130816925 chr1:g.70883695G>A single base substitution Missense: CTH C109Y|Intron: CTH

Table 6. Mutations in the TP53, VEGFA, and CTH genes in GBM retrieved from the COSMIC database.

GBM: glioblastoma

TP53 Position CDS mutation AA mutation Legacy mutation ID Count Type
1 19 c.55_59delinsA p.F19Kfs*24 COSM6943854 1 Complex - frameshift
2 339 c.1016delinsGG p.E339Gfs*8 COSM10073065 1 Complex - frameshift
3 32 c.93del p.L32Cfs*12 COSM5048959 1 Deletion - Frameshift
4 47 c.140_162del p.P47Hfs*2 COSM4968945 1 Deletion - Frameshift
5 69 c.205del p.A69Lfs*54 COSM39408 1 Deletion - Frameshift
6 80 c.239del p.P80Lfs*43 COSM45219 1 Deletion - Frameshift
7 89 c.266_267del p.P89Lfs*59 COSM10073066 1 Deletion - Frameshift
8 90 c.267del p.S90Pfs*33 COSM18610 2 Deletion - Frameshift
9 112 c.335del p.G112Afs*11 COSM6196473 1 Deletion - Frameshift
10 122 c.365_366del p.V122Dfs*26 COSM44882 1 Deletion - Frameshift
11 131 c.390_426del p.N131Cfs*27 COSM44576 2 Deletion - Frameshift
12 137 c.409del p.L137Wfs*33 COSM45058 1 Deletion - Frameshift
13 139 c.417_418del p.K139Nfs*9 COSM35650 1 Deletion - Frameshift
14 150 c.447_459del p.T150Afs*16 COSM5752221 1 Deletion - Frameshift
15 152 c.455_459del p.P152Rfs*27 COSM507584 1 Deletion - Frameshift
16 155 c.462_474del p.T155Pfs*11 COSM10077562 1 Deletion - Frameshift
17 156 c.466del p.R156Afs*14 COSM43691 1 Deletion - Frameshift
18 158 c.472del p.R158Afs*12 COSM43781 1 Deletion - Frameshift
19 158 c.473_476del p.R158Pfs*11 COSM43831 2 Deletion - Frameshift
20 160 c.478del p.M160Wfs*10 COSM45112 1 Deletion - Frameshift
21 161 c.481del p.A161Pfs*9 COSM44230 1 Deletion - Frameshift
22 164 c.491_494del p.K164Sfs*5 COSM44339 1 Deletion - Frameshift
23 164 c.491del p.K164Sfs*6 COSM44861 1 Deletion - Frameshift
24 167 c.499del p.Q167Sfs*3 COSM44336 1 Deletion - Frameshift
25 170 c.508_514del p.T170Lfs*2 COSM39398 1 Deletion - Frameshift
26 178 c.532del p.H178Tfs*69 COSM43978 1 Deletion - Frameshift
27 183 c.547_548del p.S183Rfs*2 COSM3734699 1 Deletion - Frameshift
28 185 c.553del p.S185Afs*62 COSM45314 1 Deletion - Frameshift
29 188 c.563del p.L188Rfs*59 COSM6979975 1 Deletion - Frameshift
30 190 c.567_586del p.P190Sfs*12 COSM6966898 1 Deletion - Frameshift
31 190 c.569del p.P190Lfs*57 COSM44454 1 Deletion - Frameshift
32 195 c.584del p.I195Tfs*52 COSM6201897 2 Deletion - Frameshift
33 196 c.586del p.R196Efs*51 COSM44757 1 Deletion - Frameshift
34 199 c.595_599del p.G199Ffs*8 COSM4970228 1 Deletion - Frameshift
35 200 c.599del p.N200Ifs*47 COSM43859 1 Deletion - Frameshift
36 205 c.613del p.Y205Ifs*42 COSM45525 1 Deletion - Frameshift
37 206 c.617del p.L206Wfs*41 COSM44852 1 Deletion - Frameshift
38 209 c.626_627del p.R209Kfs*6 COSM6482 5 Deletion - Frameshift
39 211 c.631del p.T211Lfs*36 COSM44371 1 Deletion - Frameshift
40 212 c.635_636del p.F212Sfs*3 COSM44162 2 Deletion - Frameshift
41 213 c.636del p.R213Dfs*34 COSM44358 2 Deletion - Frameshift
42 213 c.637del p.R213Dfs*34 COSM43807 1 Deletion - Frameshift
43 214 c.641del p.H214Lfs*33 COSM128666 1 Deletion - Frameshift
44 214 c.642_643del p.H214Qfs*7 COSM46269 2 Deletion - Frameshift
45 220 c.657del p.Y220Mfs*27 COSM44585 1 Deletion - Frameshift
46 222 c.665del p.P222Rfs*25 COSM44270 1 Deletion - Frameshift
47 231 c.691del p.T231Pfs*16 COSM45784 1 Deletion - Frameshift
48 234 c.699_705del p.Y234Tfs*11 COSM1626221 2 Deletion - Frameshift
49 235 c.703_704del p.N235Lfs*4 COSM4966998 1 Deletion - Frameshift
50 239 c.716del p.N239Tfs*8 COSM44183 1 Deletion - Frameshift
51 245 c.734del p.G245Afs*2 COSM44642 1 Deletion - Frameshift
52 256 c.766del p.T256Hfs*89 COSM45526 3 Deletion - Frameshift
53 256 c.767del p.T256Nfs*89 COSM508592 1 Deletion - Frameshift
54 262 c.785del p.G262Vfs*83 COSM44697 2 Deletion - Frameshift
55 267 c.798del p.R267Gfs*78 COSM6912585 1 Deletion - Frameshift
56 276 c.827_830del p.A276Vfs*68 COSM44342 1 Deletion - Frameshift
57 285 c.854_855del p.E285Gfs*20 COSM44337 1 Deletion - Frameshift
58 288 c.863del p.N288Ifs*57 COSM45459 1 Deletion - Frameshift
59 294 c.880del p.E294Sfs*51 COSM6621 1 Deletion - Frameshift
60 301 c.902del p.P301Qfs*44 COSM45184 1 Deletion - Frameshift
61 306 c.916del p.R306Efs*39 COSM44631 1 Deletion - Frameshift
62 313 c.936del p.S313Afs*32 COSM45392 1 Deletion - Frameshift
63 333 c.997del p.R333Vfs*12 COSM69084 1 Deletion - Frameshift
64 336 c.1005_1006del p.E336Afs*10 COSM1268340 2 Deletion - Frameshift
65 339 c.1017_1018del p.E339Dfs*7 COSM9854012 1 Deletion - Frameshift
66 342 c.1025del p.R342Qfs*3 COSM46154 1 Deletion - Frameshift
67 349 c.1045del p.E349Nfs*21 COSM46056 2 Deletion - Frameshift
68 376 c.1125_1128del p.S376Pfs*45 COSM6944989 1 Deletion - Frameshift
69 382 c.1146del p.K382Nfs*40 COSM13747 2 Deletion - Frameshift
70 57 c.169_228del p.D57_A76del COSM46324 1 Deletion - In frame
71 101 c.303_308del p.K101_Y103delinsN COSM255314 1 Deletion - In frame
72 113 c.339_341del p.F113del COSM45143 1 Deletion - In frame
73 126 c.376_396del p.Y126_K132del COSM44405 1 Deletion - In frame
74 129 c.385_387del p.A129del COSM44947 1 Deletion - In frame
75 131 c.393_395del p.N131del COSM44212 5 Deletion - In frame
76 131 c.? p.N131del COSM5991646 1 Deletion - In frame
77 153 c.450_452del p.P153del COSM6920004 1 Deletion - In frame
78 155 c.463_468del p.T155_R156del COSM46355 4 Deletion - In frame
79 157 c.470_475del p.V157_R158del COSM43727 2 Deletion - In frame
80 177 c.529_546del p.P177_C182del COSM43570 2 Deletion - In frame
81 179 c.534_536del p.H179del COSM45560 1 Deletion - In frame
82 187 c.559_561delGGT p.G187del COSM144169 1 Deletion - In frame
83 191 c.572_574del p.P191del COSM44234 3 Deletion - In frame
84 195 c.584_598del p.I195_G199del COSM44534 1 Deletion - In frame
85 225 c.674_682del p.V225_S227del COSM45452 1 Deletion - In frame
86 235 c.704_709del p.N235_Y236del COSM44333 1 Deletion - In frame
87 236 c.706_708del p.Y236del COSM44072 1 Deletion - In frame
88 238 c.712_714del p.C238del COSM46322 1 Deletion - In frame
89 239 c.716_721del p.N239_S241delinsT COSM4302130 1 Deletion - In frame
90 248 c.742_750del p.R248_P250del COSM44533 1 Deletion - In frame
91 252 c.754_756del p.L252del COSM44247 1 Deletion - In frame
92 255 c.764_766del p.I255del COSM43694 7 Deletion - In frame
93 265 c.792_794del p.L265del COSM45150 4 Deletion - In frame
94 337 c.1010_1018del p.R337_M340delinsL COSM4745947 1 Deletion - In frame
95 47 c.? p.P47fs*? COSM7002268 1 Frameshift
96 52 c.? p.Q52Xfs*71 COSM3734733 2 Frameshift
97 64 c.? p.P64Xfs*58 COSM4745856 1 Frameshift
98 68 c.? p.E68Xfs*54 COSM4745853 1 Frameshift
99 93 c.? p.L93Cfs*30 COSM6024076 1 Frameshift
100 121 c.? p.S121fs*? COSM7002259 1 Frameshift
101 122 c.? p.V122Xfs*25 COSM4745854 1 Frameshift
102 150 c.? p.T150fs*? COSM7002261 1 Frameshift
103 152 c.? p.P152Rfs*18 COSM9114970 1 Frameshift
104 152 c.? p.P152Xfs*18 COSM4603663 1 Frameshift
105 174 c.? p.R174* COSM4603631 2 Frameshift
106 199 c.? p.G199fs*? COSM7002260 1 Frameshift
107 209 c.? p.R209Xfs*6 COSM5945684 2 Frameshift
108 215 c.? p.S215Xfs*? COSM1169531 1 Frameshift
109 218 c.? p.V218Gfs*4 COSM7002371 1 Frameshift
110 237 c.? p.M237Ifs*10 COSM6024042 1 Frameshift
111 260 c.? p.S260fs*3 COSM4745861 1 Frameshift
112 278 c.? p.P278Lfs*67 COSM6024043 1 Frameshift
113 284 c.? p.T284fs*? COSM5945723 1 Frameshift
114 290 c.? p.R290Qfs*15 COSM6024041 1 Frameshift
115 305 c.? p.K305Xfs*40 COSM4766151 1 Frameshift
116 42 c.116_123dup p.D42Qfs*5 COSM6948685 1 Insertion - Frameshift
117 97 c.289dup p.V97Gfs*52 COSM10077571 1 Insertion - Frameshift
118 122 c.363dup p.V122Cfs*27 COSM8266503 2 Insertion - Frameshift
119 124 c.372del p.C124* COSM69020 1 Insertion - Frameshift
120 133 c.383_396dup p.M133Lfs*42 COSM6968586 1 Insertion - Frameshift
121 139 c.414_415insNNNN p.K139fs*11 COSM46321 1 Insertion - Frameshift
122 146 c.434_435insNN p.W146fs*25 COSM46262 1 Insertion - Frameshift
123 171 c.510_511dup p.E171Gfs*4 COSM7481695 1 Insertion - Frameshift
124 173 c.516_517insN p.V173fs*8 COSM43546 1 Insertion - Frameshift
125 176 c.528_541delinsA p.C176* COSM6925117 1 Insertion - Frameshift
126 182 c.542_543dup p.C182Afs*66 COSM4971129 1 Insertion - Frameshift
127 193 c.575dup p.H193Afs*16 COSM10536703 6 Insertion - Frameshift
128 217 c.648_649insNNNNNNNN p.V217fs*33 COSM46216 1 Insertion - Frameshift
129 218 c.652dup p.V218Gfs*4 COSM6969098 1 Insertion - Frameshift
130 239 c.714_715insN p.N239fs*25 COSM44155 2 Insertion - Frameshift
131 261 c.769_781dup p.S261Tfs*7 COSM9869125 1 Insertion - Frameshift
132 302 c.902dup p.G302Rfs*4 COSM4745930 1 Insertion - Frameshift
133 308 c.895_919dup p.L308Afs*6 COSM6934703 1 Insertion - Frameshift
134 308 c.920-3_920dup p.L308Sfs*30 COSM6923871 1 Insertion - Frameshift
135 316 c.945_946dup p.P316Lfs*30 COSM6964186 1 Insertion - Frameshift
136 342 c.1024del p.R342Efs*3 COSM18597 3 Insertion - Frameshift
137 142 c.423_425dup p.P142dup COSM6934393 1 Insertion - In frame
138 157 c.469_471dup p.V157dup COSM144168 1 Insertion - In frame
139 184 c.548_549insGCCCCCACCATGAGCGCTGCT p.S183_D184insPPP*ALL COSM674055 1 Insertion - In frame
140 232 c.680_694dup p.T231_I232insTDCTT COSM6974264 1 Insertion - In frame
141 238 c.714_715insNNN p.C238_N239insX COSM44532 1 Insertion - In frame
142 254 c.759_760insCTC p.T253_I254insL COSM10077583 1 Insertion - In frame
143 84 c.252C>T p.A84= COSM45512 1 Substitution - coding silent
144 125 c.375G>A p.T125= COSM43904 5 Substitution - coding silent
145 125 c.375G>T p.T125= COSM45940 1 Substitution - coding silent
146 126 c.378C>T p.Y126= COSM44196 1 Substitution - coding silent
147 137 c.411G>A p.L137= COSM44649 1 Substitution - coding silent
148 149 c.447C>T p.S149= COSM44408 1 Substitution - coding silent
149 157 c.471C>A p.V157= COSM43934 1 Substitution - coding silent
150 173 c.519G>T p.V173= COSM43752 1 Substitution - coding silent
151 177 c.531C>T p.P177= COSM43679 2 Substitution - coding silent
152 196 c.586C>A p.R196= COSM44615 1 Substitution - coding silent
153 213 c.637C>A p.R213= COSM43798 1 Substitution - coding silent
154 213 c.639A>G p.R213= COSM249885 2 Substitution - coding silent
155 224 c.672G>A p.E224= COSM44754 1 Substitution - coding silent
156 248 c.742C>A p.R248= COSM44920 1 Substitution - coding silent
157 261 c.783T>C p.S261= COSM43748 1 Substitution - coding silent
158 265 c.795G>A p.L265= COSM43785 1 Substitution - coding silent
159 301 c.903A>G p.P301= COSM44165 1 Substitution - coding silent
160 306 c.918A>T p.R306= COSM43745 1 Substitution - coding silent
161 320 c.960G>A p.K320= COSM44197 1 Substitution - coding silent
162 324 c.972T>C p.D324= COSM45815 1 Substitution - coding silent
163 3 c.? p.E3G COSM5945685 1 Substitution - Missense
164 10 c.29T>G p.V10G COSM510151 1 Substitution - Missense
165 27 c.? p.P27L COSM5945686 1 Substitution - Missense
166 49 c.145G>A p.D49N COSM305601 1 Substitution - Missense
167 60 c.178C>G p.P60A COSM39514 1 Substitution - Missense
168 60 c.179C>G p.P60R COSM39453 1 Substitution - Missense
169 64 c.190C>T p.P64S COSM6976875 1 Substitution - Missense
170 65 c.? p.R65K COSM4169574 1 Substitution - Missense
171 67 c.199C>T p.P67S COSM44199 1 Substitution - Missense
172 68 c.203A>G p.E68G COSM44790 1 Substitution - Missense
173 72 c.215C>G p.P72R COSM250061 3 Substitution - Missense
174 72 c.? p.P72R COSM5346903 1 Substitution - Missense
175 73 c.218T>A p.V73E COSM44556 1 Substitution - Missense
176 74 c.? p.A74V COSM221572 1 Substitution - Missense
177 76 c.? p.A76T COSM221566 1 Substitution - Missense
178 81 c.242C>T p.T81I COSM44200 1 Substitution - Missense
179 84 c.251C>T p.A84V COSM44194 2 Substitution - Missense
180 84 c.? p.A84V COSM221567 1 Substitution - Missense
181 85 c.253C>T p.P85S COSM45918 2 Substitution - Missense
182 85 c.? p.P85L COSM6849516 1 Substitution - Missense
183 86 c.? p.A86E COSM4169575 1 Substitution - Missense
184 86 c.? p.A86S COSM221569 1 Substitution - Missense
185 87 c.260C>A p.P87Q COSM43544 1 Substitution - Missense
186 98 c.293C>T p.P98L COSM44681 1 Substitution - Missense
187 98 c.? p.P98L COSM4169573 1 Substitution - Missense
188 105 c.313G>A p.G105S COSM78687 1 Substitution - Missense
189 105 c.313G>C p.G105R COSM45179 3 Substitution - Missense
190 105 c.? p.G105S COSM1666889 1 Substitution - Missense
191 106 c.? p.S106R COSM4745858 1 Substitution - Missense
192 109 c.325T>G p.F109V COSM48817 2 Substitution - Missense
193 109 c.326T>C p.F109S COSM45169 1 Substitution - Missense
194 110 c.328C>T p.R110C COSM43682 1 Substitution - Missense
195 110 c.329G>C p.R110P COSM11250 2 Substitution - Missense
196 110 c.329G>T p.R110L COSM10716 2 Substitution - Missense
197 111 c.331C>A p.L111M COSM43790 1 Substitution - Missense
198 111 c.332T>A p.L111Q COSM44630 1 Substitution - Missense
199 111 c.332T>C p.L111P COSM44045 1 Substitution - Missense
200 111 c.332T>G p.L111R COSM44570 1 Substitution - Missense
201 111 c.? p.L111P COSM5033525 1 Substitution - Missense
202 113 c.337T>G p.F113V COSM11498 2 Substitution - Missense
203 113 c.? p.F113L COSM1169535 2 Substitution - Missense
204 120 c.358A>G p.K120E COSM44827 3 Substitution - Missense
205 120 c.359A>T p.K120M COSM44190 2 Substitution - Missense
206 120 c.? p.K120E COSM4745863 2 Substitution - Missense
207 123 c.368C>T p.T123I COSM44188 1 Substitution - Missense
208 124 c.370T>C p.C124R COSM11147 1 Substitution - Missense
209 124 c.? p.C124R COSM5033526 2 Substitution - Missense
210 125 c.373A>C p.T125P COSM45368 1 Substitution - Missense
211 125 c.374C>G p.T125R COSM45243 4 Substitution - Missense
212 125 c.374C>T p.T125M COSM44988 1 Substitution - Missense
213 125 c.? p.T125R COSM4745855 1 Substitution - Missense
214 126 c.376T>A p.Y126N COSM44380 2 Substitution - Missense
215 126 c.376T>G p.Y126D COSM43900 2 Substitution - Missense
216 126 c.377A>G p.Y126C COSM11517 1 Substitution - Missense
217 126 c.? p.Y126H COSM4169572 1 Substitution - Missense
218 127 c.379T>A p.S127T COSM53285 1 Substitution - Missense
219 127 c.380C>A p.S127Y COSM43970 4 Substitution - Missense
220 127 c.380C>G p.S127C COSM45483 1 Substitution - Missense
221 127 c.380C>T p.S127F COSM44226 13 Substitution - Missense
222 127 c.? p.S127F COSM1651680 3 Substitution - Missense
223 127 c.? p.S127Y COSM6024039 1 Substitution - Missense
224 128 c.383C>T p.P128L COSM45131 1 Substitution - Missense
225 130 c.388C>G p.L130V COSM11462 1 Substitution - Missense
226 130 c.388C>T p.L130F COSM11449 3 Substitution - Missense
227 130 c.389T>A p.L130H COSM46114 1 Substitution - Missense
228 130 c.389T>C p.L130P COSM45481 2 Substitution - Missense
229 130 c.? p.L130F COSM9973967 2 Substitution - Missense
230 131 c.392A>G p.N131S COSM44474 1 Substitution - Missense
231 131 c.392A>T p.N131I COSM44794 2 Substitution - Missense
232 132 c.394A>C p.K132Q COSM11224 1 Substitution - Missense
233 132 c.394A>G p.K132E COSM10813 5 Substitution - Missense
234 132 c.395A>C p.K132T COSM43912 2 Substitution - Missense
235 132 c.395A>G p.K132R COSM11582 2 Substitution - Missense
236 132 c.395A>T p.K132M COSM43592 1 Substitution - Missense
237 132 c.396G>C p.K132N COSM43963 4 Substitution - Missense
238 132 c.396G>T p.K132N COSM10991 2 Substitution - Missense
239 132 c.? p.K132M COSM7002263 1 Substitution - Missense
240 132 c.? p.K132R COSM166371 2 Substitution - Missense
241 133 c.398T>G p.M133R COSM43730 1 Substitution - Missense
242 133 c.? p.M133V COSM221570 1 Substitution - Missense
243 134 c.400T>G p.F134V COSM43941 1 Substitution - Missense
244 134 c.401T>C p.F134S COSM44506 1 Substitution - Missense
245 134 c.401T>G p.F134C COSM43949 2 Substitution - Missense
246 134 c.? p.F134L COSM1169422 1 Substitution - Missense
247 135 c.403T>A p.C135S COSM44910 1 Substitution - Missense
248 135 c.403T>G p.C135G COSM44829 1 Substitution - Missense
249 135 c.404G>A p.C135Y COSM10801 4 Substitution - Missense
250 135 c.405C>G p.C135W COSM44219 5 Substitution - Missense
251 135 c.? p.C135G COSM221571 1 Substitution - Missense
252 135 c.? p.C135W COSM4169704 1 Substitution - Missense
253 135 c.? p.C135Y COSM674226 1 Substitution - Missense
254 136 c.406C>G p.Q136E COSM43767 5 Substitution - Missense
255 138 c.412G>A p.A138T COSM44821 1 Substitution - Missense
256 138 c.412G>C p.A138P COSM11188 3 Substitution - Missense
257 138 c.413C>T p.A138V COSM43818 4 Substitution - Missense
258 138 c.? p.A138P COSM5546571 2 Substitution - Missense
259 138 c.? p.A138V COSM330609 1 Substitution - Missense
260 139 c.417G>C p.K139N COSM44101 2 Substitution - Missense
261 140 c.419C>T p.T140I COSM43742 4 Substitution - Missense
262 141 c.421T>C p.C141R COSM43901 1 Substitution - Missense
263 141 c.421T>G p.C141G COSM45794 1 Substitution - Missense
264 141 c.422G>A p.C141Y COSM43708 9 Substitution - Missense
265 141 c.422G>T p.C141F COSM44911 1 Substitution - Missense
266 141 c.423C>G p.C141W COSM44204 1 Substitution - Missense
267 142 c.425C>T p.P142L COSM43583 1 Substitution - Missense
268 143 c.427G>A p.V143M COSM43878 2 Substitution - Missense
269 145 c.433C>G p.L145V COSM45885 1 Substitution - Missense
270 145 c.434T>C p.L145P COSM43899 3 Substitution - Missense
271 146 c.436T>G p.W146G COSM44555 1 Substitution - Missense
272 151 c.451C>A p.P151T COSM43911 2 Substitution - Missense
273 151 c.451C>G p.P151A COSM44944 1 Substitution - Missense
274 151 c.451C>T p.P151S COSM10905 7 Substitution - Missense
275 151 c.452C>G p.P151R COSM44003 1 Substitution - Missense
276 151 c.452C>T p.P151L COSM44288 1 Substitution - Missense
277 151 c.? p.P151S COSM133656 2 Substitution - Missense
278 152 c.454C>A p.P152T COSM44561 3 Substitution - Missense
279 152 c.454C>G p.P152A COSM44788 1 Substitution - Missense
280 152 c.454C>T p.P152S COSM43582 1 Substitution - Missense
281 152 c.455C>A p.P152Q COSM44613 1 Substitution - Missense
282 152 c.455C>T p.P152L COSM10790 21 Substitution - Missense
283 152 c.? p.P152L COSM143793 1 Substitution - Missense
284 152 c.? p.P152R COSM1716294 1 Substitution - Missense
285 152 c.? p.P152S COSM4745862 1 Substitution - Missense
286 153 c.458C>T p.P153L COSM44367 1 Substitution - Missense
287 155 c.463A>C p.T155P COSM10912 1 Substitution - Missense
288 155 c.463A>G p.T155A COSM44303 1 Substitution - Missense
289 155 c.464C>A p.T155N COSM11218 7 Substitution - Missense
290 155 c.464C>T p.T155I COSM44033 1 Substitution - Missense
291 156 c.466C>A p.R156S COSM43744 2 Substitution - Missense
292 156 c.466C>T p.R156C COSM46124 1 Substitution - Missense
293 156 c.467G>A p.R156H COSM43739 1 Substitution - Missense
294 156 c.467G>C p.R156P COSM10760 1 Substitution - Missense
295 156 c.467G>T p.R156L COSM43548 1 Substitution - Missense
296 156 c.? p.R156G COSM4766148 1 Substitution - Missense
297 157 c.469G>T p.V157F COSM10670 9 Substitution - Missense
298 157 c.470T>A p.V157D COSM44329 1 Substitution - Missense
299 157 c.470T>G p.V157G COSM43903 3 Substitution - Missense
300 157 c.? p.V157F COSM144151 6 Substitution - Missense
301 158 c.472C>A p.R158S COSM3970360 2 Substitution - Missense
302 158 c.472C>G p.R158G COSM11087 8 Substitution - Missense
303 158 c.472C>T p.R158C COSM43848 2 Substitution - Missense
304 158 c.473G>A p.R158H COSM10690 21 Substitution - Missense
305 158 c.473G>C p.R158P COSM43615 3 Substitution - Missense
306 158 c.473G>T p.R158L COSM10714 3 Substitution - Missense
307 158 c.473_474delinsTT p.R158L COSM44974 1 Substitution - Missense
308 158 c.? p.R158G COSM1651671 1 Substitution - Missense
309 158 c.? p.R158H COSM330667 2 Substitution - Missense
310 159 c.475G>C p.A159P COSM43836 1 Substitution - Missense
311 159 c.476C>A p.A159D COSM11496 2 Substitution - Missense
312 159 c.476C>T p.A159V COSM11148 3 Substitution - Missense
313 161 c.481G>A p.A161T COSM10739 7 Substitution - Missense
314 161 c.481G>T p.A161S COSM43549 1 Substitution - Missense
315 161 c.482C>A p.A161D COSM11323 2 Substitution - Missense
316 161 c.482C>G p.A161G COSM46279 1 Substitution - Missense
317 161 c.482C>T p.A161V COSM43689 1 Substitution - Missense
318 161 c.? p.A161T COSM306126 7 Substitution - Missense
319 162 c.484A>G p.I162V COSM44413 1 Substitution - Missense
320 162 c.484A>T p.I162F COSM44320 1 Substitution - Missense
321 162 c.? p.I162F COSM4745852 1 Substitution - Missense
322 163 c.487T>A p.Y163N COSM44623 2 Substitution - Missense
323 163 c.487T>C p.Y163H COSM43846 2 Substitution - Missense
324 163 c.488A>G p.Y163C COSM10808 13 Substitution - Missense
325 163 c.? p.Y163H COSM5945683 1 Substitution - Missense
326 164 c.490A>G p.K164E COSM10762 2 Substitution - Missense
327 164 c.492G>T p.K164N COSM11369 1 Substitution - Missense
328 164 c.? p.K164E COSM1169394 1 Substitution - Missense
329 165 c.495G>C p.Q165H COSM4302127 1 Substitution - Missense
330 165 c.495G>T p.Q165H COSM44558 1 Substitution - Missense
331 165 c.? p.Q165P COSM4766149 1 Substitution - Missense
332 166 c.496_497delinsGG p.S166G COSM43932 1 Substitution - Missense
333 168 c.503A>G p.H168R COSM43545 3 Substitution - Missense
334 168 c.? p.H168R COSM4745864 1 Substitution - Missense
335 168 c.? p.H168Y COSM7002258 1 Substitution - Missense
336 170 c.509C>T p.T170M COSM44552 1 Substitution - Missense
337 171 c.512A>G p.E171G COSM44732 2 Substitution - Missense
338 172 c.514G>T p.V172F COSM44240 1 Substitution - Missense
339 172 c.515T>G p.V172G COSM45047 2 Substitution - Missense
340 172 c.? p.V172F COSM133680 1 Substitution - Missense
341 173 c.517G>A p.V173M COSM11084 5 Substitution - Missense
342 173 c.517G>C p.V173L COSM44057 1 Substitution - Missense
343 173 c.517G>T p.V173L COSM43559 7 Substitution - Missense
344 173 c.518T>C p.V173A COSM44327 7 Substitution - Missense
345 173 c.518T>G p.V173G COSM44383 1 Substitution - Missense
346 173 c.? p.V173A COSM7002265 1 Substitution - Missense
347 174 c.520A>T p.R174W COSM44782 1 Substitution - Missense
348 174 c.521G>A p.R174K COSM44524 1 Substitution - Missense
349 175 c.523C>A p.R175S COSM43931 1 Substitution - Missense
350 175 c.523C>G p.R175G COSM10870 2 Substitution - Missense
351 175 c.523C>T p.R175C COSM43680 2 Substitution - Missense
352 175 c.524G>A p.R175H COSM10648 123 Substitution - Missense
353 175 c.524G>C p.R175P COSM45416 1 Substitution - Missense
354 175 c.524G>T p.R175L COSM10718 1 Substitution - Missense
355 175 c.? p.R175C COSM4169629 1 Substitution - Missense
356 175 c.? p.R175H COSM144210 19 Substitution - Missense
357 175 c.? p.R175S COSM221568 1 Substitution - Missense
358 176 c.526T>C p.C176R COSM44948 3 Substitution - Missense
359 176 c.527G>A p.C176Y COSM10687 8 Substitution - Missense
360 176 c.527G>T p.C176F COSM10645 13 Substitution - Missense
361 177 c.529C>T p.P177S COSM10650 1 Substitution - Missense
362 177 c.530C>A p.P177H COSM45326 1 Substitution - Missense
363 177 c.530C>G p.P177R COSM10651 5 Substitution - Missense
364 177 c.530C>T p.P177L COSM44097 1 Substitution - Missense
365 178 c.533A>C p.H178P COSM44215 4 Substitution - Missense
366 178 c.534C>A p.H178Q COSM11998 2 Substitution - Missense
367 179 c.535C>A p.H179N COSM44151 1 Substitution - Missense
368 179 c.535C>G p.H179D COSM44776 4 Substitution - Missense
369 179 c.535C>T p.H179Y COSM10768 8 Substitution - Missense
370 179 c.536A>C p.H179P COSM44218 1 Substitution - Missense
371 179 c.536A>G p.H179R COSM10889 32 Substitution - Missense
372 179 c.536A>T p.H179L COSM43635 1 Substitution - Missense
373 179 c.537T>A p.H179Q COSM44214 1 Substitution - Missense
374 179 c.537T>G p.H179Q COSM11249 2 Substitution - Missense
375 179 c.? p.H179D COSM7002262 1 Substitution - Missense
376 179 c.? p.H179Y COSM133679 1 Substitution - Missense
377 180 c.? p.E180K COSM330664 1 Substitution - Missense
378 181 c.541C>T p.R181C COSM11090 5 Substitution - Missense
379 181 c.542G>A p.R181H COSM10738 4 Substitution - Missense
380 181 c.542G>C p.R181P COSM45046 3 Substitution - Missense
381 183 c.547T>C p.S183P COSM44343 1 Substitution - Missense
382 184 c.550G>T p.D184Y COSM44202 1 Substitution - Missense
383 186 c.557A>G p.D186G COSM46287 1 Substitution - Missense
384 187 c.? p.G187S COSM219079 1 Substitution - Missense
385 188 c.562C>A p.L188M COSM3727816 1 Substitution - Missense
386 190 c.568C>T p.P190S COSM44682 4 Substitution - Missense
387 190 c.569C>G p.P190R COSM44004 3 Substitution - Missense
388 190 c.569C>T p.P190L COSM43657 6 Substitution - Missense
389 190 c.? p.P190L COSM133661 3 Substitution - Missense
390 193 c.577C>A p.H193N COSM43935 2 Substitution - Missense
391 193 c.577C>G p.H193D COSM44002 1 Substitution - Missense
392 193 c.577C>T p.H193Y COSM10672 10 Substitution - Missense
393 193 c.578A>C p.H193P COSM43833 3 Substitution - Missense
394 193 c.578A>G p.H193R COSM10742 17 Substitution - Missense
395 193 c.578A>T p.H193L COSM11066 4 Substitution - Missense
396 193 c.? p.H193L COSM330673 1 Substitution - Missense
397 193 c.? p.H193R COSM1716523 1 Substitution - Missense
398 193 c.? p.H193Y COSM7002267 1 Substitution - Missense
399 194 c.581T>G p.L194R COSM44571 2 Substitution - Missense
400 194 c.? p.L194R COSM4172004 2 Substitution - Missense
401 195 c.583A>T p.I195F COSM44633 2 Substitution - Missense
402 195 c.584T>A p.I195N COSM44877 2 Substitution - Missense
403 195 c.584T>C p.I195T COSM11089 11 Substitution - Missense
404 195 c.? p.I195F COSM1666654 1 Substitution - Missense
405 196 c.587G>A p.R196Q COSM44599 1 Substitution - Missense
406 196 c.587G>C p.R196P COSM43814 2 Substitution - Missense
407 197 c.590T>A p.V197E COSM44424 1 Substitution - Missense
408 199 c.595G>A p.G199R COSM43749 3 Substitution - Missense
409 199 c.596G>A p.G199E COSM43989 1 Substitution - Missense
410 199 c.596G>T p.G199V COSM44140 2 Substitution - Missense
411 199 c.? p.G199E COSM5985110 1 Substitution - Missense
412 200 c.599A>C p.N200T COSM45331 1 Substitution - Missense
413 203 c.607G>A p.V203M COSM43599 1 Substitution - Missense
414 205 c.613T>C p.Y205H COSM43642 1 Substitution - Missense
415 205 c.613T>G p.Y205D COSM43844 2 Substitution - Missense
416 205 c.614A>C p.Y205S COSM44169 4 Substitution - Missense
417 205 c.614A>G p.Y205C COSM43947 6 Substitution - Missense
418 205 c.? p.Y205C COSM330677 1 Substitution - Missense
419 205 c.? p.Y205H COSM146252 1 Substitution - Missense
420 208 c.623A>G p.D208G COSM45796 1 Substitution - Missense
421 208 c.623A>T p.D208V COSM44249 2 Substitution - Missense
422 208 c.624C>A p.D208E COSM45707 1 Substitution - Missense
423 208 c.? p.D208Y COSM4745859 1 Substitution - Missense
424 210 c.628A>G p.N210D COSM43933 1 Substitution - Missense
425 211 c.632C>T p.T211I COSM43939 6 Substitution - Missense
426 213 c.637C>G p.R213G COSM44102 1 Substitution - Missense
427 213 c.638G>A p.R213Q COSM10735 5 Substitution - Missense
428 213 c.638G>T p.R213L COSM43650 2 Substitution - Missense
429 213 c.? p.R213Q COSM146253 3 Substitution - Missense
430 213 c.? p.R213W COSM4745857 1 Substitution - Missense
431 214 c.640C>G p.H214D COSM45115 1 Substitution - Missense
432 214 c.641A>G p.H214R COSM43687 11 Substitution - Missense
433 214 c.? p.H214R COSM1169410 1 Substitution - Missense
434 215 c.643A>G p.S215G COSM43951 5 Substitution - Missense
435 215 c.644G>A p.S215N COSM44093 1 Substitution - Missense
436 215 c.644G>C p.S215T COSM44175 1 Substitution - Missense
437 215 c.644G>T p.S215I COSM11450 2 Substitution - Missense
438 215 c.? p.S215R COSM3734734 1 Substitution - Missense
439 216 c.646G>A p.V216M COSM10667 11 Substitution - Missense
440 216 c.646G>T p.V216L COSM11210 1 Substitution - Missense
441 216 c.? p.V216M COSM143796 1 Substitution - Missense
442 217 c.649G>T p.V217L COSM44334 1 Substitution - Missense
443 217 c.? p.V217G COSM9989106 1 Substitution - Missense
444 218 c.653T>G p.V218G COSM44198 2 Substitution - Missense
445 219 c.656C>G p.P219R COSM44053 1 Substitution - Missense
446 220 c.658T>C p.Y220H COSM44637 1 Substitution - Missense
447 220 c.658T>G p.Y220D COSM11847 1 Substitution - Missense
448 220 c.659A>C p.Y220S COSM43850 1 Substitution - Missense
449 220 c.659A>G p.Y220C COSM10758 39 Substitution - Missense
450 220 c.? p.Y220C COSM96438 4 Substitution - Missense
451 220 c.? p.Y220S COSM1577275 2 Substitution - Missense
452 222 c.665C>T p.P222L COSM44606 1 Substitution - Missense
453 224 c.671A>G p.E224G COSM44014 1 Substitution - Missense
454 224 c.672G>C p.E224D COSM44945 1 Substitution - Missense
455 224 c.672G>T p.E224D COSM11451 1 Substitution - Missense
456 227 c.680C>T p.S227F COSM43920 1 Substitution - Missense
457 228 c.682G>T p.D228Y COSM45786 1 Substitution - Missense
458 230 c.688A>C p.T230P COSM44271 1 Substitution - Missense
459 230 c.689C>T p.T230I COSM43868 2 Substitution - Missense
460 232 c.695T>G p.I232S COSM45045 2 Substitution - Missense
461 234 c.700T>A p.Y234N COSM43956 1 Substitution - Missense
462 234 c.700T>C p.Y234H COSM11152 2 Substitution - Missense
463 234 c.700T>G p.Y234D COSM43768 1 Substitution - Missense
464 234 c.701A>G p.Y234C COSM10725 13 Substitution - Missense
465 234 c.? p.Y234H COSM4766150 1 Substitution - Missense
466 235 c.703A>G p.N235D COSM11542 1 Substitution - Missense
467 235 c.704A>G p.N235S COSM43616 3 Substitution - Missense
468 236 c.706T>A p.Y236N COSM43826 2 Substitution - Missense
469 236 c.706T>G p.Y236D COSM43602 1 Substitution - Missense
470 236 c.707A>C p.Y236S COSM44693 1 Substitution - Missense
471 236 c.707A>G p.Y236C COSM10731 5 Substitution - Missense
472 236 c.? p.Y236N COSM1169561 1 Substitution - Missense
473 237 c.709A>G p.M237V COSM44525 2 Substitution - Missense
474 237 c.711G>A p.M237I COSM10834 14 Substitution - Missense
475 237 c.711G>T p.M237I COSM11063 3 Substitution - Missense
476 237 c.? p.M237I COSM46274 5 Substitution - Missense
477 238 c.713G>A p.C238Y COSM11059 11 Substitution - Missense
478 238 c.713G>C p.C238S COSM44653 3 Substitution - Missense
479 238 c.713G>T p.C238F COSM43778 3 Substitution - Missense
480 238 c.? p.C238Y COSM166370 2 Substitution - Missense
481 239 c.715A>G p.N239D COSM10777 2 Substitution - Missense
482 239 c.716A>G p.N239S COSM44094 1 Substitution - Missense
483 239 c.717C>G p.N239K COSM44510 1 Substitution - Missense
484 239 c.? p.N239T COSM4603632 1 Substitution - Missense
485 240 c.718A>G p.S240G COSM43973 3 Substitution - Missense
486 240 c.719G>C p.S240T COSM44964 1 Substitution - Missense
487 241 c.721T>C p.S241P COSM44578 1 Substitution - Missense
488 241 c.721T>G p.S241A COSM44224 2 Substitution - Missense
489 241 c.722C>A p.S241Y COSM10935 3 Substitution - Missense
490 241 c.722C>T p.S241F COSM10812 11 Substitution - Missense
491 241 c.? p.S241F COSM329738 4 Substitution - Missense
492 241 c.? p.S241Y COSM1717459 1 Substitution - Missense
493 242 c.724T>A p.C242S COSM44935 1 Substitution - Missense
494 242 c.724T>C p.C242R COSM11738 1 Substitution - Missense
495 242 c.725G>A p.C242Y COSM10646 6 Substitution - Missense
496 242 c.725G>C p.C242S COSM11133 2 Substitution - Missense
497 242 c.725G>T p.C242F COSM10810 3 Substitution - Missense
498 242 c.? p.C242S COSM330665 1 Substitution - Missense
499 242 c.? p.C242Y COSM330672 2 Substitution - Missense
500 243 c.727A>C p.M243L COSM43765 1 Substitution - Missense
501 244 c.730G>A p.G244S COSM10941 6 Substitution - Missense
502 244 c.730G>C p.G244R COSM44221 1 Substitution - Missense
503 244 c.731G>A p.G244D COSM10883 5 Substitution - Missense
504 244 c.731G>T p.G244V COSM43652 1 Substitution - Missense
505 244 c.? p.G244S COSM330669 2 Substitution - Missense
506 245 c.733G>A p.G245S COSM6932 52 Substitution - Missense
507 245 c.733G>C p.G245R COSM10957 1 Substitution - Missense
508 245 c.733G>T p.G245C COSM11081 1 Substitution - Missense
509 245 c.734G>A p.G245D COSM43606 5 Substitution - Missense
510 245 c.734G>T p.G245V COSM11196 5 Substitution - Missense
511 245 c.? p.G245D COSM143788 5 Substitution - Missense
512 245 c.? p.G245S COSM145022 14 Substitution - Missense
513 245 c.? p.G245V COSM1162159 1 Substitution - Missense
514 246 c.736A>G p.M246V COSM43555 4 Substitution - Missense
515 246 c.737T>C p.M246T COSM11355 1 Substitution - Missense
516 246 c.737T>G p.M246R COSM11376 3 Substitution - Missense
517 246 c.738G>A p.M246I COSM44310 2 Substitution - Missense
518 246 c.? p.M246I COSM1732649 2 Substitution - Missense
519 246 c.? p.M246T COSM330615 1 Substitution - Missense
520 248 c.742C>G p.R248G COSM11564 1 Substitution - Missense
521 248 c.742C>T p.R248W COSM10656 63 Substitution - Missense
522 248 c.743G>A p.R248Q COSM10662 77 Substitution - Missense
523 248 c.743G>T p.R248L COSM6549 1 Substitution - Missense
524 248 c.? p.R248Q COSM87196 12 Substitution - Missense
525 248 c.? p.R248W COSM144150 7 Substitution - Missense
526 249 c.745A>G p.R249G COSM10668 5 Substitution - Missense
527 249 c.746G>C p.R249T COSM43665 4 Substitution - Missense
528 249 c.746G>T p.R249M COSM43871 1 Substitution - Missense
529 249 c.747G>C p.R249S COSM10785 1 Substitution - Missense
530 249 c.747G>T p.R249S COSM10817 4 Substitution - Missense
531 249 c.? p.R249S COSM133090 1 Substitution - Missense
532 250 c.749C>G p.P250R COSM8257737 1 Substitution - Missense
533 250 c.749C>T p.P250L COSM10771 6 Substitution - Missense
534 251 c.751A>C p.I251L COSM10931 1 Substitution - Missense
535 251 c.752T>G p.I251S COSM43829 1 Substitution - Missense
536 252 c.755T>A p.L252H COSM45091 1 Substitution - Missense
537 252 c.755T>C p.L252P COSM44769 2 Substitution - Missense
538 252 c.? p.L252P COSM7002266 1 Substitution - Missense
539 254 c.760A>C p.I254L COSM1579892 1 Substitution - Missense
540 254 c.761T>C p.I254T COSM44058 1 Substitution - Missense
541 254 c.761T>G p.I254S COSM45035 4 Substitution - Missense
542 255 c.763A>T p.I255F COSM43651 2 Substitution - Missense
543 255 c.764T>A p.I255N COSM11244 1 Substitution - Missense
544 255 c.764T>G p.I255S COSM10788 2 Substitution - Missense
545 256 c.767C>A p.T256K COSM44429 2 Substitution - Missense
546 256 c.? p.T256K COSM7002323 2 Substitution - Missense
547 257 c.769C>G p.L257V COSM43699 2 Substitution - Missense
548 257 c.770T>A p.L257Q COSM43530 1 Substitution - Missense
549 258 c.772G>A p.E258K COSM10988 3 Substitution - Missense
550 258 c.772G>C p.E258Q COSM10751 1 Substitution - Missense
551 258 c.773A>C p.E258A COSM44719 1 Substitution - Missense
552 258 c.773A>G p.E258G COSM44168 1 Substitution - Missense
553 258 c.773A>T p.E258V COSM44450 5 Substitution - Missense
554 258 c.? p.E258K COSM1732658 1 Substitution - Missense
555 258 c.? p.E258Q COSM5945719 1 Substitution - Missense
556 259 c.775G>C p.D259H COSM46185 1 Substitution - Missense
557 259 c.776A>T p.D259V COSM43724 1 Substitution - Missense
558 262 c.785G>T p.G262V COSM11198 2 Substitution - Missense
559 263 c.? p.N263K COSM7002264 1 Substitution - Missense
560 265 c.794T>C p.L265P COSM11011 1 Substitution - Missense
561 265 c.794T>G p.L265R COSM44092 1 Substitution - Missense
562 266 c.796G>A p.G266R COSM10794 13 Substitution - Missense
563 266 c.796G>C p.G266R COSM11205 2 Substitution - Missense
564 266 c.797G>A p.G266E COSM10867 5 Substitution - Missense
565 266 c.797G>T p.G266V COSM10958 2 Substitution - Missense
566 266 c.? p.G266E COSM330616 1 Substitution - Missense
567 266 c.? p.G266R COSM6908524 1 Substitution - Missense
568 267 c.799C>T p.R267W COSM11183 15 Substitution - Missense
569 267 c.800G>A p.R267Q COSM43923 4 Substitution - Missense
570 267 c.800G>C p.R267P COSM11392 2 Substitution - Missense
571 267 c.? p.R267W COSM1169538 1 Substitution - Missense
572 269 c.806G>T p.S269I COSM4302129 2 Substitution - Missense
573 270 c.808T>C p.F270L COSM44262 1 Substitution - Missense
574 270 c.809T>C p.F270S COSM11305 3 Substitution - Missense
575 271 c.811G>A p.E271K COSM10719 2 Substitution - Missense
576 271 c.812A>G p.E271G COSM43879 2 Substitution - Missense
577 272 c.814G>A p.V272M COSM10891 9 Substitution - Missense
578 272 c.814G>T p.V272L COSM10859 3 Substitution - Missense
579 272 c.815T>C p.V272A COSM44294 1 Substitution - Missense
580 272 c.? p.V272L COSM133678 3 Substitution - Missense
581 272 c.? p.V272M COSM166369 1 Substitution - Missense
582 273 c.817C>G p.R273G COSM43843 1 Substitution - Missense
583 273 c.817C>T p.R273C COSM10659 277 Substitution - Missense
584 273 c.817_818delinsTA p.R273Y COSM6906023 1 Substitution - Missense
585 273 c.818G>A p.R273H COSM10660 87 Substitution - Missense
586 273 c.818G>C p.R273P COSM43896 3 Substitution - Missense
587 273 c.818G>T p.R273L COSM10779 6 Substitution - Missense
588 273 c.? p.R273C COSM144162 43 Substitution - Missense
589 273 c.? p.R273H COSM133677 20 Substitution - Missense
590 273 c.? p.R273L COSM144153 2 Substitution - Missense
591 274 c.820G>A p.V274I COSM43667 1 Substitution - Missense
592 274 c.820G>T p.V274F COSM10769 1 Substitution - Missense
593 274 c.821T>C p.V274A COSM44393 2 Substitution - Missense
594 274 c.821T>G p.V274G COSM43945 1 Substitution - Missense
595 275 c.823T>C p.C275R COSM43902 1 Substitution - Missense
596 275 c.823T>G p.C275G COSM11501 3 Substitution - Missense
597 275 c.824G>A p.C275Y COSM10893 8 Substitution - Missense
598 275 c.824G>T p.C275F COSM10701 9 Substitution - Missense
599 275 c.825T>G p.C275W COSM43823 1 Substitution - Missense
600 275 c.? p.C275R COSM329747 2 Substitution - Missense
601 275 c.? p.C275Y COSM330617 1 Substitution - Missense
602 276 c.827C>A p.A276D COSM45268 4 Substitution - Missense
603 276 c.827C>G p.A276G COSM45695 1 Substitution - Missense
604 276 c.827C>T p.A276V COSM10756 2 Substitution - Missense
605 276 c.? p.A276G COSM1732655 1 Substitution - Missense
606 277 c.829T>C p.C277R COSM45871 1 Substitution - Missense
607 277 c.830G>A p.C277Y COSM43737 1 Substitution - Missense
608 277 c.830G>T p.C277F COSM10749 4 Substitution - Missense
609 277 c.831T>G p.C277W COSM45299 1 Substitution - Missense
610 278 c.832C>A p.P278T COSM43697 2 Substitution - Missense
611 278 c.832C>G p.P278A COSM10814 1 Substitution - Missense
612 278 c.832C>T p.P278S COSM10939 5 Substitution - Missense
613 278 c.833C>A p.P278H COSM43755 3 Substitution - Missense
614 278 c.833C>G p.P278R COSM10887 1 Substitution - Missense
615 278 c.833C>T p.P278L COSM10863 6 Substitution - Missense
616 278 c.? p.P278L COSM5352238 1 Substitution - Missense
617 278 c.? p.P278S COSM330674 2 Substitution - Missense
618 279 c.836G>A p.G279E COSM43714 8 Substitution - Missense
619 279 c.? p.G279E COSM4603630 1 Substitution - Missense
620 280 c.838A>G p.R280G COSM11123 4 Substitution - Missense
621 280 c.839G>A p.R280K COSM10728 4 Substitution - Missense
622 280 c.839G>C p.R280T COSM10724 3 Substitution - Missense
623 280 c.839G>T p.R280I COSM11287 1 Substitution - Missense
624 280 c.840A>T p.R280S COSM44171 1 Substitution - Missense
625 280 c.? p.R280G COSM1666590 2 Substitution - Missense
626 280 c.? p.R280I COSM6024595 1 Substitution - Missense
627 280 c.? p.R280T COSM166372 2 Substitution - Missense
628 281 c.841G>A p.D281N COSM43596 4 Substitution - Missense
629 281 c.841G>C p.D281H COSM10943 9 Substitution - Missense
630 281 c.842A>C p.D281A COSM11665 2 Substitution - Missense
631 281 c.842A>G p.D281G COSM11232 1 Substitution - Missense
632 281 c.842A>T p.D281V COSM45729 1 Substitution - Missense
633 281 c.843C>G p.D281E COSM43837 3 Substitution - Missense
634 281 c.843_844delinsGT p.D281_R282delinsEW COSM45816 1 Substitution - Missense
635 281 c.? p.D281E COSM133657 1 Substitution - Missense
636 281 c.? p.D281H COSM7338405 1 Substitution - Missense
637 282 c.844C>G p.R282G COSM10992 1 Substitution - Missense
638 282 c.844C>T p.R282W COSM10704 60 Substitution - Missense
639 282 c.845G>A p.R282Q COSM44338 1 Substitution - Missense
640 282 c.? p.R282W COSM96436 7 Substitution - Missense
641 283 c.847C>T p.R283C COSM10911 2 Substitution - Missense
642 283 c.848G>C p.R283P COSM10743 1 Substitution - Missense
643 283 c.? p.R283C COSM87043 2 Substitution - Missense
644 283 c.? p.R283H COSM6834791 1 Substitution - Missense
645 284 c.850A>T p.T284S COSM4302128 1 Substitution - Missense
646 285 c.853G>A p.E285K COSM10722 4 Substitution - Missense
647 285 c.854A>T p.E285V COSM44227 1 Substitution - Missense
648 286 c.856G>A p.E286K COSM10726 5 Substitution - Missense
649 286 c.856G>C p.E286Q COSM44250 1 Substitution - Missense
650 286 c.857A>G p.E286G COSM43565 2 Substitution - Missense
651 286 c.857A>T p.E286V COSM43936 1 Substitution - Missense
652 286 c.? p.E286G COSM4745865 1 Substitution - Missense
653 289 c.866T>G p.L289R COSM44344 1 Substitution - Missense
654 290 c.869G>A p.R290H COSM44017 1 Substitution - Missense
655 291 c.872A>G p.K291R COSM43747 1 Substitution - Missense
656 293 c.877G>T p.G293W COSM46261 1 Substitution - Missense
657 294 c.881A>G p.E294G COSM43746 1 Substitution - Missense
658 298 c.894G>C p.E298D COSM4589938 1 Substitution - Missense
659 305 c.914A>G p.K305R COSM43743 2 Substitution - Missense
660 307 c.920C>T p.A307V COSM35846 2 Substitution - Missense
661 313 c.938G>A p.S313N COSM44557 1 Substitution - Missense
662 324 c.? p.D324N COSM9975897 1 Substitution - Missense
663 329 c.? p.T329I COSM5945722 1 Substitution - Missense
664 331 c.993G>T p.Q331H COSM96339 1 Substitution - Missense
665 335 c.? p.R335C COSM5945724 1 Substitution - Missense
666 336 c.? p.E336K COSM6849515 1 Substitution - Missense
667 337 c.1009C>T p.R337C COSM11071 9 Substitution - Missense
668 337 c.? p.R337C COSM6024625 1 Substitution - Missense
669 342 c.1025G>C p.R342P COSM45276 3 Substitution - Missense
670 347 c.1039G>A p.A347T COSM45717 2 Substitution - Missense
671 347 c.1040C>G p.A347G COSM46323 1 Substitution - Missense
672 347 c.? p.A347T COSM10134010 1 Substitution - Missense
673 364 c.1090G>A p.A364T COSM46361 1 Substitution - Missense
674 373 c.1118A>G p.K373R COSM3727817 1 Substitution - Missense
675 375 c.1123C>A p.Q375K COSM3403253 1 Substitution - Missense
676 379 c.1136G>A p.R379H COSM44189 2 Substitution - Missense
677 392 c.1174T>C p.S392P COSM6950049 1 Substitution - Missense
678 5 c.13C>T p.Q5* COSM44191 1 Substitution - Nonsense
679 23 c.68G>A p.W23* COSM6916925 1 Substitution - Nonsense
680 53 c.158G>A p.W53* COSM44760 3 Substitution - Nonsense
681 53 c.159G>A p.W53* COSM44488 2 Substitution - Nonsense
682 53 c.? p.W53* COSM329729 1 Substitution - Nonsense
683 56 c.166G>T p.E56* COSM12168 1 Substitution - Nonsense
684 68 c.? p.E68* COSM4603637 1 Substitution - Nonsense
685 91 c.272G>A p.W91* COSM44192 3 Substitution - Nonsense
686 91 c.? p.W91* COSM4169625 1 Substitution - Nonsense
687 94 c.281C>G p.S94* COSM45653 1 Substitution - Nonsense
688 100 c.298C>T p.Q100* COSM44032 1 Substitution - Nonsense
689 136 c.406C>T p.Q136* COSM11166 6 Substitution - Nonsense
690 141 c.? p.C141* COSM221573 1 Substitution - Nonsense
691 144 c.430C>T p.Q144* COSM11245 1 Substitution - Nonsense
692 146 c.437G>A p.W146* COSM43609 6 Substitution - Nonsense
693 146 c.438G>A p.W146* COSM10727 5 Substitution - Nonsense
694 164 c.490A>T p.K164* COSM10750 1 Substitution - Nonsense
695 167 c.499C>T p.Q167* COSM11333 1 Substitution - Nonsense
696 167 c.? p.Q167* COSM146254 1 Substitution - Nonsense
697 176 c.? p.C176* COSM4745860 1 Substitution - Nonsense
698 183 c.548C>G p.S183* COSM10706 4 Substitution - Nonsense
699 192 c.574C>T p.Q192* COSM10733 2 Substitution - Nonsense
700 196 c.586C>T p.R196* COSM10705 28 Substitution - Nonsense
701 196 c.? p.R196* COSM143787 2 Substitution - Nonsense
702 213 c.637C>T p.R213* COSM10654 23 Substitution - Nonsense
703 213 c.? p.R213* COSM166368 6 Substitution - Nonsense
704 221 c.661G>T p.E221* COSM44817 2 Substitution - Nonsense
705 234 c.702C>A p.Y234* COSM45114 2 Substitution - Nonsense
706 238 c.714T>A p.C238* COSM45677 1 Substitution - Nonsense
707 271 c.811G>T p.E271* COSM43750 1 Substitution - Nonsense
708 273 c.? p.R273* COSM144152 1 Substitution - Nonsense
709 286 c.856G>T p.E286* COSM43919 1 Substitution - Nonsense
710 298 c.? p.E298* COSM133654 1 Substitution - Nonsense
711 306 c.916C>T p.R306* COSM10663 21 Substitution - Nonsense
712 306 c.? p.R306* COSM145026 6 Substitution - Nonsense
713 317 c.949C>T p.Q317* COSM10786 3 Substitution - Nonsense
714 317 c.? p.Q317* COSM1169548 1 Substitution - Nonsense
715 320 c.958A>T p.K320* COSM44335 2 Substitution - Nonsense
716 327 c.981T>G p.Y327* COSM44823 1 Substitution - Nonsense
717 331 c.991C>T p.Q331* COSM11354 1 Substitution - Nonsense
718 336 c.1006G>T p.E336* COSM11291 2 Substitution - Nonsense
719 339 c.1015G>T p.E339* COSM11286 4 Substitution - Nonsense
720 342 c.1024C>T p.R342* COSM11073 22 Substitution - Nonsense
721 342 c.? p.R342* COSM306146 10 Substitution - Nonsense
722 348 c.1043T>A p.L348* COSM46015 1 Substitution - Nonsense
723 349 c.1045G>T p.E349* COSM10770 1 Substitution - Nonsense
724 191 c.? p.? COSM44855 1 Unknown
725 - c.75-1G>A p.? COSM6983171 1 Unknown
726 - c.96+1G>A p.? COSM44435 2 Unknown
727 - c.96+1G>T p.? COSM307275 4 Unknown
728 - c.97-11_103del p.? COSM6969464 1 Unknown
729 - c.97-1G>A p.? COSM43759 1 Unknown
730 - c.97-1G>C p.? COSM29761 1 Unknown
731 - c.97-1G>T p.? COSM1610880 1 Unknown
732 - c.97-2A>G p.? COSM39405 2 Unknown
733 - c.375+1G>A p.? COSM45304 2 Unknown
734 - c.375+1G>C p.? COSM45910 1 Unknown
735 - c.375+6T>G p.? COSM4969482 1 Unknown
736 - c.376-1G>A p.? COSM6900 5 Unknown
737 - c.376-2A>C p.? COSM46049 1 Unknown
738 - c.376-2A>G p.? COSM45672 1 Unknown
739 - c.376-2del p.? COSM45658 1 Unknown
740 - c.548_559+2del p.? COSM6905819 1 Unknown
741 - c.559+13_559+14del p.? COSM44193 1 Unknown
742 - c.559+1G>A p.? COSM6901 3 Unknown
743 - c.560-1G>A p.? COSM43753 5 Unknown
744 - c.560-22A>G p.? COSM45665 1 Unknown
745 - c.560-2A>G p.? COSM18657 1 Unknown
746 - c.560-3T>G p.? COSM46059 1 Unknown
747 - c.672+1G>A p.? COSM6906 2 Unknown
748 - c.672+2T>C p.? COSM45517 1 Unknown
749 - c.673-1G>A p.? COSM43751 2 Unknown
750 - c.673-1G>C p.? COSM45675 1 Unknown
751 - c.673-2A>G p.? COSM6908 2 Unknown
752 - c.673-41_673-33delinsCAGAGCCCA p.? COSM46260 1 Unknown
753 - c.782+42C>T p.? COSM44039 1 Unknown
754 - c.783-1G>T p.? COSM6913 1 Unknown
755 - c.783-1_789del p.? COSM9114976 1 Unknown
756 - c.783-2A>C p.? COSM13744 2 Unknown
757 - c.919+1G>A p.? COSM44143 1 Unknown
758 - c.919+1G>C p.? COSM13585 2 Unknown
759 - c.919+1G>T p.? COSM13584 2 Unknown
760 - c.919+6C>T p.? COSM44195 1 Unknown
761 - c.920-1G>A p.? COSM6917 2 Unknown
762 - c.920-2A>G p.? COSM33650 2 Unknown
763 - c.987_993+6del p.? COSM4970898 1 Unknown
764 - c.993+291G>A p.? COSM5977671 1 Unknown
765 - c.993+2T>C p.? COSM45552 1 Unknown
766 - c.993+982G>C p.? COSN6549382 1 Unknown
767 - c.994-1G>A p.? COSM69404 2 Unknown
768 - c.994-1G>C p.? COSM13745 1 Unknown
769 - c.994-2A>C p.? COSM3970337 1 Unknown
770 - c.994-2A>G p.? COSM87027 1 Unknown
771 - c.*387C>A p.? COSN20093202 1 Unknown
772 - c.? p.? COSM43617 385 Unknown
773 1 c.1_*del p.0 COSM18654 4 Whole gene deletion
VEGFA Position CDS Mutation AA Mutation Legacy Mutation ID Count Type
1 97 c.291G>A p.E97= COSM9202275 1 Substitution - coding silent
2 265 c.795C>T p.G265= COSM9209991 3 Substitution - coding silent
3 239 c.715G>A p.V239M COSM6928938 1 Substitution - Missense
4 257 c.770G>A p.C257Y COSM6974477 1 Substitution - Missense
5 351 c.1052G>A p.R351H COSM296967 1 Substitution - Missense
6 323 c.969T>A p.C323* COSM7482303 1 Substitution - Nonsense
7 361 c.1081G>T p.E361* COSM8259731 1 Substitution - Nonsense
8 - c.-363T>C p.? COSN6590948 1 Unknown
9 - c.855+1G>A p.? COSM9209993 3 Unknown
10 - c.963-1214C>T p.? COSM248279 1 Unknown
11 - c.*60A>T p.? COSM3411133 1 Unknown
12 - c.*78C>T p.? COSN30102404 1 Unknown
CTH Position CDS Mutation AA Mutation Legacy Mutation ID Count Type
1 62 c.185G>T p.R62L COSM3400990 1 Substitution - Missense
2 332 c.995G>T p.R332I COSM7473216 1 Substitution - Missense
3 - c.-144C>G p.? COSN30101590 2 Unknown
4 - c.*140T>A p.? COSN30104531 1 Unknown

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Scientific Research Division's Research Ethics Committee of University of Duhok issued approval 15092021-9-13. All procedures contributing to this work met national and institutional human experimentation committees' ethical standards and the Declaration of Helsinki.

Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Author Contributions

Concept and design:  Abbas Salihi, Sardar S. Khalil

Acquisition, analysis, or interpretation of data:  Abbas Salihi, Sardar S. Khalil

Drafting of the manuscript:  Abbas Salihi, Sardar S. Khalil

Critical review of the manuscript for important intellectual content:  Abbas Salihi, Sardar S. Khalil

Supervision:  Abbas Salihi

References

  • 1.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. CA Cancer J Clin. 2021;71:209–249. doi: 10.3322/caac.21660. [DOI] [PubMed] [Google Scholar]
  • 2.The 2021 WHO classification for gliomas and implications on imaging diagnosis: part 1-key points of the fifth edition and summary of imaging findings on adult-type diffuse gliomas. Park YW, Vollmuth P, Foltyn-Dumitru M, Sahm F, Ahn SS, Chang JH, Kim SH. J Magn Reson Imaging. 2023;58:677–689. doi: 10.1002/jmri.28743. [DOI] [PubMed] [Google Scholar]
  • 3.Angiogenesis in glioblastoma. Das S, Marsden PA. N Engl J Med. 2013;369:1561–1563. doi: 10.1056/NEJMcibr1309402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Genetic variations in VEGF and VEGFR2 and glioblastoma outcome. Sjöström S, Wibom C, Andersson U, et al. J Neurooncol. 2011;104:523–527. doi: 10.1007/s11060-010-0504-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Prognostic value of ATRX and p53 status in high-grade glioma patients in Morocco. Squalli Houssaini A, Lamrabet S, Senhaji N, et al. Cureus. 2024;16:0. doi: 10.7759/cureus.56361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Wang Y, Yang J, Zheng H, et al. Cancer Cell. 2009;15:514–526. doi: 10.1016/j.ccr.2009.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hydrogen sulfide signaling in mitochondria and disease. Murphy B, Bhattacharya R, Mukherjee P. FASEB J. 2019;33:13098–13125. doi: 10.1096/fj.201901304R. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Dysregulation of cystathionine γ-lyase promotes prostate cancer progression and metastasis. Wang YH, Huang JT, Chen WL, et al. EMBO Rep. 2019;20:0. doi: 10.15252/embr.201845986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.In vitro anticancer activity of hydrogen sulfide and nitric oxide alongside nickel nanoparticle and novel mutations in their genes in CRC patients. Housein Z, Kareem TS, Salihi A. Sci Rep. 2021;11:2536. doi: 10.1038/s41598-021-82244-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.NOS3 and CTH gene mutations as new molecular markers for detection of lung adenocarcinoma. Abdullah Ramadhan I, Rahman Sulaiman L, Salihi A. PeerJ. 2023;11:0. doi: 10.7717/peerj.16209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Impact of age and gender on glioblastoma onset, progression, and management. Colopi A, Fuda S, Santi S, et al. Mech Ageing Dev. 2023;211:111801. doi: 10.1016/j.mad.2023.111801. [DOI] [PubMed] [Google Scholar]
  • 12.Management of glioblastoma in elderly patients: a review of the literature. Mazarakis NK, Robinson SD, Sinha P, et al. Clin Transl Radiat Oncol. 2024;46:100761. doi: 10.1016/j.ctro.2024.100761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Tumor microenvironment in glioblastoma: current and emerging concepts. Sharma P, Aaroe A, Liang J, Puduvalli VK. Neurooncol Adv. 2023;5:0. doi: 10.1093/noajnl/vdad009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Dialogue among lymphocytes and microglia in glioblastoma microenvironment. Mormino A, Garofalo S. Cancers (Basel) 2022;14:2632. doi: 10.3390/cancers14112632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Myeloid cells in glioblastoma microenvironment. De Leo A, Ugolini A, Veglia F. Cells. 2020;10:18. doi: 10.3390/cells10010018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Tumor-associated macrophages in gliomas-basic insights and treatment opportunities. Andersen JK, Miletic H, Hossain JA. Cancers (Basel) 2022;14:1319. doi: 10.3390/cancers14051319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Increasing C-reactive protein levels in a patient with glioblastoma with lymph node metastasis: a case report. Kanemitsu T, Furuse M, Kuwabara H, et al. BMC Neurol. 2023;23:354. doi: 10.1186/s12883-023-03402-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. Sarganas G, Orzechowski HD, Klimpel A, et al. Neuro Oncol. 2012;14:541–546. doi: 10.1093/neuonc/nos056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Cancer. p53, guardian of the genome. Lane DP. Nature. 1992;358:15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  • 20.TP53 mutations in human cancer: database reassessment and prospects for the next decade. Leroy B, Anderson M, Soussi T. Hum Mutat. 2014;35:672–688. doi: 10.1002/humu.22552. [DOI] [PubMed] [Google Scholar]
  • 21.The IARC TP53 database: new online mutation analysis and recommendations to users. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. Hum Mutat. 2002;19:607–614. doi: 10.1002/humu.10081. [DOI] [PubMed] [Google Scholar]
  • 22.Association between the serum concentrations and mutational status of IL-8, IL-27 and VEGF and the expression levels of the hERG potassium channel gene in patients with colorectal cancer. Abid MN, Qadir FA, Salihi A. Oncol Lett. 2021;22:665. doi: 10.3892/ol.2021.12926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Possible involvement of silent mutations in cancer pathogenesis and evolution. Kikutake C, Suyama M. Sci Rep. 2023;13:7593. doi: 10.1038/s41598-023-34452-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.The p53 pathway in glioblastoma. Zhang Y, Dube C, Gibert M Jr, et al. Cancers (Basel) 2018;10 doi: 10.3390/cancers10090297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Targeting p53 pathways: mechanisms, structures, and advances in therapy. Wang H, Guo M, Wei H, Chen Y. Signal Transduct Target Ther. 2023;8:92. doi: 10.1038/s41392-023-01347-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding. Liu Y, Kulesz-Martin M. Carcinogenesis. 2001;22:851–860. doi: 10.1093/carcin/22.6.851. [DOI] [PubMed] [Google Scholar]
  • 27.VEGF promotes proliferation of human glioblastoma multiforme stem-like cells through VEGF receptor 2. Xu C, Wu X, Zhu J. ScientificWorldJournal. 2013;2013:417413. doi: 10.1155/2013/417413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. Reardon DA, Turner S, Peters KB, et al. J Natl Compr Canc Netw. 2011;9:414–427. doi: 10.6004/jnccn.2011.0038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Severe consequences of a high-lipid diet include hydrogen sulfide dysfunction and enhanced aggression in glioblastoma. Silver DJ, Roversi GA, Bithi N, et al. J Clin Invest. 2021;131 doi: 10.1172/JCI138276. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES